WO1998018810A1 - Immunostimulatory nucleic acid molecules - Google Patents
Immunostimulatory nucleic acid molecules Download PDFInfo
- Publication number
- WO1998018810A1 WO1998018810A1 PCT/US1997/019791 US9719791W WO9818810A1 WO 1998018810 A1 WO1998018810 A1 WO 1998018810A1 US 9719791 W US9719791 W US 9719791W WO 9818810 A1 WO9818810 A1 WO 9818810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- cpg
- odn
- acid sequence
- cells
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 152
- 102000039446 nucleic acids Human genes 0.000 title claims description 103
- 108020004707 nucleic acids Proteins 0.000 title claims description 103
- 230000003308 immunostimulating effect Effects 0.000 title description 42
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 112
- 230000004936 stimulating effect Effects 0.000 claims abstract description 51
- 239000002671 adjuvant Substances 0.000 claims abstract description 24
- 230000004663 cell proliferation Effects 0.000 claims abstract description 17
- 230000005934 immune activation Effects 0.000 claims abstract description 13
- 230000002101 lytic effect Effects 0.000 claims abstract description 13
- 230000016396 cytokine production Effects 0.000 claims abstract description 9
- 230000000638 stimulation Effects 0.000 claims description 75
- 108090001005 Interleukin-6 Proteins 0.000 claims description 74
- 102000004889 Interleukin-6 Human genes 0.000 claims description 74
- 230000004913 activation Effects 0.000 claims description 70
- 102000004127 Cytokines Human genes 0.000 claims description 50
- 108090000695 Cytokines Proteins 0.000 claims description 50
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 50
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 42
- 108010065805 Interleukin-12 Proteins 0.000 claims description 29
- 102000013462 Interleukin-12 Human genes 0.000 claims description 29
- 230000004048 modification Effects 0.000 claims description 25
- 238000012986 modification Methods 0.000 claims description 25
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 23
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 22
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 22
- 229960003677 chloroquine Drugs 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 208000006673 asthma Diseases 0.000 claims description 18
- 230000020477 pH reduction Effects 0.000 claims description 18
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 17
- 230000001404 mediated effect Effects 0.000 claims description 16
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 15
- 108010074328 Interferon-gamma Proteins 0.000 claims description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 102100037850 Interferon gamma Human genes 0.000 claims description 13
- 210000000265 leukocyte Anatomy 0.000 claims description 13
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 12
- 229940113082 thymine Drugs 0.000 claims description 12
- 108091029430 CpG site Proteins 0.000 claims description 11
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 9
- 229940104302 cytosine Drugs 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 239000013638 trimer Substances 0.000 claims description 7
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 6
- 229930024421 Adenine Natural products 0.000 claims description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 5
- 229930191564 Monensin Natural products 0.000 claims description 5
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims description 5
- 229960000643 adenine Drugs 0.000 claims description 5
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 claims description 5
- 229960005358 monensin Drugs 0.000 claims description 5
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- XDHNQDDQEHDUTM-XJKSCTEHSA-N (3z,5e,7r,8s,9r,11e,13e,15s,16r)-16-[(2s,3r,4s)-4-[(2r,4r,5s,6r)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one Chemical compound CO[C@H]1\C=C\C=C(C)\C[C@@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(OC)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-XJKSCTEHSA-N 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract description 27
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 297
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 264
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 260
- 108020004414 DNA Proteins 0.000 description 189
- 210000004027 cell Anatomy 0.000 description 160
- 230000000694 effects Effects 0.000 description 72
- 108091034117 Oligonucleotide Proteins 0.000 description 65
- 230000028327 secretion Effects 0.000 description 49
- 230000004044 response Effects 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 43
- 230000001965 increasing effect Effects 0.000 description 42
- 230000006698 induction Effects 0.000 description 41
- 239000003642 reactive oxygen metabolite Substances 0.000 description 41
- 241000588724 Escherichia coli Species 0.000 description 40
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 38
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 36
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 36
- 241001529936 Murinae Species 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 35
- 239000002158 endotoxin Substances 0.000 description 33
- 229920006008 lipopolysaccharide Polymers 0.000 description 33
- 210000004698 lymphocyte Anatomy 0.000 description 32
- 238000004519 manufacturing process Methods 0.000 description 31
- 210000004989 spleen cell Anatomy 0.000 description 31
- 235000013601 eggs Nutrition 0.000 description 30
- 239000000427 antigen Substances 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 28
- 108020000946 Bacterial DNA Proteins 0.000 description 27
- 230000027455 binding Effects 0.000 description 27
- 229940117681 interleukin-12 Drugs 0.000 description 27
- 210000001541 thymus gland Anatomy 0.000 description 27
- 238000003556 assay Methods 0.000 description 26
- 238000001727 in vivo Methods 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 25
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 23
- 210000004072 lung Anatomy 0.000 description 23
- 244000309466 calf Species 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 150000004713 phosphodiesters Chemical class 0.000 description 20
- 102000005869 Activating Transcription Factors Human genes 0.000 description 19
- 108010005254 Activating Transcription Factors Proteins 0.000 description 19
- 101710163270 Nuclease Proteins 0.000 description 18
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 18
- 230000003844 B-cell-activation Effects 0.000 description 17
- 230000000692 anti-sense effect Effects 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 230000007246 mechanism Effects 0.000 description 17
- 210000000822 natural killer cell Anatomy 0.000 description 17
- -1 CpG nucleic acids Chemical class 0.000 description 16
- 210000001616 monocyte Anatomy 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 238000007792 addition Methods 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 230000015556 catabolic process Effects 0.000 description 14
- 238000006731 degradation reaction Methods 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 13
- 210000000987 immune system Anatomy 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 12
- 230000017306 interleukin-6 production Effects 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 11
- 230000003389 potentiating effect Effects 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 210000003979 eosinophil Anatomy 0.000 description 10
- 230000011987 methylation Effects 0.000 description 10
- 238000007069 methylation reaction Methods 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 229940104230 thymidine Drugs 0.000 description 10
- 230000002103 transcriptional effect Effects 0.000 description 10
- 238000011765 DBA/2 mouse Methods 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 9
- 229940045145 uridine Drugs 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 8
- 150000003212 purines Chemical class 0.000 description 8
- 230000003393 splenic effect Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000006306 Antigen Receptors Human genes 0.000 description 7
- 108010083359 Antigen Receptors Proteins 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 7
- 239000013566 allergen Substances 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 230000004700 cellular uptake Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 230000002297 mitogenic effect Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 150000003230 pyrimidines Chemical class 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 238000012827 research and development Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 210000001163 endosome Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 6
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010063593 DNA modification methylase SssI Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000242680 Schistosoma mansoni Species 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- KZELNMSPWPFAEB-UMMCILCDSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-8-sulfanylidene-3,7-dihydropurin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2NC(=S)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KZELNMSPWPFAEB-UMMCILCDSA-N 0.000 description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 101150013553 CD40 gene Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 4
- 229940103893 gliotoxin Drugs 0.000 description 4
- 229930190252 gliotoxin Natural products 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- WXJXBKBJAKPJRN-UHFFFAOYSA-N Methanephosphonothioic acid Chemical class CP(O)(O)=S WXJXBKBJAKPJRN-UHFFFAOYSA-N 0.000 description 3
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 239000003430 antimalarial agent Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 3
- 230000029069 type 2 immune response Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 2
- 241000219496 Alnus Species 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 230000024704 B cell apoptotic process Effects 0.000 description 2
- 102000001764 CREB-Binding Protein Human genes 0.000 description 2
- 108010040163 CREB-Binding Protein Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 244000281762 Chenopodium ambrosioides Species 0.000 description 2
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 2
- 235000005490 Chenopodium botrys Nutrition 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 240000005109 Cryptomeria japonica Species 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 241000721662 Juniperus Species 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AJMOLNFDYWTVQW-QWRGUYRKSA-N L-leucyl-l-leucine methyl ester Chemical compound COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C AJMOLNFDYWTVQW-QWRGUYRKSA-N 0.000 description 2
- 241000239218 Limulus Species 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 241000795633 Olea <sea slug> Species 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108091081548 Palindromic sequence Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 description 2
- 206010053879 Sepsis syndrome Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000218636 Thuja Species 0.000 description 2
- 102000000160 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Human genes 0.000 description 2
- 108010080432 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Proteins 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000010398 acute inflammatory response Effects 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 230000003172 anti-dna Effects 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 229930192649 bafilomycin Natural products 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000005868 ontogenesis Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003003 phosphines Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000004911 positive regulation of CREB transcription factor activity Effects 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000277 virosome Substances 0.000 description 2
- CGRCVIZBNRUWLY-HNNXBMFYSA-N (2s)-2-[(4-methylphenyl)sulfonylamino]-3-phenylpropanoic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CGRCVIZBNRUWLY-HNNXBMFYSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 102000039549 ATF family Human genes 0.000 description 1
- 108091067350 ATF family Proteins 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 108010044688 Activating Transcription Factor 2 Proteins 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 241000209136 Agropyron Species 0.000 description 1
- 241000743339 Agrostis Species 0.000 description 1
- 240000005611 Agrostis gigantea Species 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical group C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 241000743857 Anthoxanthum Species 0.000 description 1
- 240000004178 Anthoxanthum odoratum Species 0.000 description 1
- 235000014251 Anthoxanthum odoratum Nutrition 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000508787 Arrhenatherum Species 0.000 description 1
- 241000508786 Arrhenatherum elatius Species 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000219429 Betula Species 0.000 description 1
- 235000003932 Betula Nutrition 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000238658 Blattella Species 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000209200 Bromus Species 0.000 description 1
- 241000743756 Bromus inermis Species 0.000 description 1
- 102000015280 CCAAT-Enhancer-Binding Protein-beta Human genes 0.000 description 1
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000723437 Chamaecyparis Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 241000723198 Cupressus Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000209210 Dactylis Species 0.000 description 1
- 240000004585 Dactylis glomerata Species 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 241000238713 Dermatophagoides farinae Species 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000508725 Elymus repens Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000234642 Festuca Species 0.000 description 1
- 241000234645 Festuca pratensis Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000057766 Gymnostoma chamaecyparis Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000226709 Hesperocyparis arizonica Species 0.000 description 1
- 241001290232 Hesperocyparis macrocarpa Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000744855 Holcus Species 0.000 description 1
- 240000003857 Holcus lanatus Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 230000004950 I-kappaB phosphorylation Effects 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 241000721668 Juniperus ashei Species 0.000 description 1
- 241000592238 Juniperus communis Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 244000100545 Lolium multiflorum Species 0.000 description 1
- 240000004296 Lolium perenne Species 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 102100033457 NF-kappa-B inhibitor beta Human genes 0.000 description 1
- 101710204094 NF-kappa-B inhibitor beta Proteins 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- QWZRZYWLWTWVLF-UHFFFAOYSA-N O.OP(O)=O Chemical compound O.OP(O)=O QWZRZYWLWTWVLF-UHFFFAOYSA-N 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001465379 Parietaria judaica Species 0.000 description 1
- 241000721464 Parietaria officinalis Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001330453 Paspalum Species 0.000 description 1
- 241001330451 Paspalum notatum Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000238661 Periplaneta Species 0.000 description 1
- 241000238675 Periplaneta americana Species 0.000 description 1
- 241000745991 Phalaris Species 0.000 description 1
- 244000081757 Phalaris arundinacea Species 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 241000746981 Phleum Species 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000209048 Poa Species 0.000 description 1
- 241000136254 Poa compressa Species 0.000 description 1
- 241000209049 Poa pratensis Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 244000274906 Quercus alba Species 0.000 description 1
- 235000009137 Quercus alba Nutrition 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101150002130 Rb1 gene Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 244000004774 Sabina virginiana Species 0.000 description 1
- 235000008691 Sabina virginiana Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 244000082988 Secale cereale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000701033 Simian cytomegalovirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 240000006694 Stellaria media Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000035100 Threonine proteases Human genes 0.000 description 1
- 108091005501 Threonine proteases Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 102000006290 Transcription Factor TFIID Human genes 0.000 description 1
- 108010083268 Transcription Factor TFIID Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- RICLFGYGYQXUFH-UHFFFAOYSA-N buspirone hydrochloride Chemical compound [H+].[Cl-].C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 RICLFGYGYQXUFH-UHFFFAOYSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- BOKOVLFWCAFYHP-UHFFFAOYSA-N dihydroxy-methoxy-sulfanylidene-$l^{5}-phosphane Chemical compound COP(O)(O)=S BOKOVLFWCAFYHP-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 230000013764 eosinophil chemotaxis Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 229940116886 human interleukin-6 Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
- DHYWDEXXBWTTEH-UHFFFAOYSA-N odn 2007 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)C(O)C1 DHYWDEXXBWTTEH-UHFFFAOYSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- ZORAAXQLJQXLOD-UHFFFAOYSA-N phosphonamidous acid Chemical compound NPO ZORAAXQLJQXLOD-UHFFFAOYSA-N 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- WIFGCZCFSNIILK-UHFFFAOYSA-N platinum;pyrimidine Chemical class [Pt].C1=CN=CN=C1 WIFGCZCFSNIILK-UHFFFAOYSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108010005709 protein kinase C kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- QQWNHZQFJMLQMI-UHFFFAOYSA-N pyrrolidin-1-ylsulfanylphosphonamidous acid Chemical class C1CCN(C1)SP(N)O QQWNHZQFJMLQMI-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000005334 regulation of lymphocyte activation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000724775 unclassified viruses Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU52424/98A AU5242498A (en) | 1996-10-30 | 1997-10-30 | Immunostimulatory nucleic acid molecules |
JP52078498A JP2001503267A (en) | 1996-10-30 | 1997-10-30 | Immunostimulatory nucleic acid molecule |
EP97947311A EP0948510B1 (en) | 1996-10-30 | 1997-10-30 | Immunostimulatory nucleic acid molecules |
NZ335397A NZ335397A (en) | 1996-10-30 | 1997-10-30 | Immunostimulatory unmethylated CpG dinucleotides |
DE69736331T DE69736331T2 (en) | 1996-10-30 | 1997-10-30 | IMMUNOSTIMULATING NUCLEIC ACID MOLECULES |
CA2270345A CA2270345C (en) | 1996-10-30 | 1997-10-30 | Immunostimulatory nucleic acid molecules |
AU97249/01A AU775185B2 (en) | 1996-10-30 | 2001-12-14 | Immunostimulatory nucleic acid molecules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/738,652 US6207646B1 (en) | 1994-07-15 | 1996-10-30 | Immunostimulatory nucleic acid molecules |
US08/738,652 | 1996-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998018810A1 true WO1998018810A1 (en) | 1998-05-07 |
Family
ID=24968901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/019791 WO1998018810A1 (en) | 1996-10-30 | 1997-10-30 | Immunostimulatory nucleic acid molecules |
Country Status (14)
Country | Link |
---|---|
US (32) | US6207646B1 (en) |
EP (5) | EP1746159A3 (en) |
JP (5) | JP2001503267A (en) |
KR (1) | KR100689942B1 (en) |
CN (2) | CN101265285A (en) |
AT (1) | ATE332966T1 (en) |
AU (3) | AU5242498A (en) |
CA (1) | CA2270345C (en) |
DE (1) | DE69736331T2 (en) |
DK (1) | DK0948510T3 (en) |
ES (2) | ES2624859T3 (en) |
NZ (1) | NZ335397A (en) |
PT (1) | PT948510E (en) |
WO (1) | WO1998018810A1 (en) |
Cited By (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998049288A1 (en) * | 1997-04-30 | 1998-11-05 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
WO1998055495A2 (en) * | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO1999011275A3 (en) * | 1997-09-05 | 1999-06-03 | Univ California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
WO1999056755A1 (en) * | 1998-05-06 | 1999-11-11 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
WO1999058118A2 (en) * | 1998-05-14 | 1999-11-18 | Cpg Immunopharmaceuticals Gmbh | METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
WO1999061056A2 (en) * | 1998-05-22 | 1999-12-02 | Loeb Health Research Institute At The Ottawa Hospital | Methods and products for inducing mucosal immunity |
WO2000006588A1 (en) * | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
WO2000021556A1 (en) * | 1998-10-09 | 2000-04-20 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
US6083505A (en) * | 1992-04-16 | 2000-07-04 | 3M Innovative Properties Company | 1H-imidazo[4,5-C]quinolin-4-amines as vaccine adjuvants |
WO2000050075A2 (en) * | 1999-02-26 | 2000-08-31 | Chiron S.P.A. | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
FR2790955A1 (en) * | 1999-03-19 | 2000-09-22 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
GB2348132A (en) * | 1999-03-02 | 2000-09-27 | Nassief Nida Abdul Ghani | Uses for glycophosphopeptical |
EP1039935A1 (en) * | 1997-02-28 | 2000-10-04 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
WO2000062803A2 (en) * | 1999-04-15 | 2000-10-26 | Board Of Regents, The University Of Texas System | ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS |
WO2000062802A2 (en) * | 1999-04-20 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Vaccine comprising rsv antigen and cpg oligonucleotide |
WO2000062800A2 (en) * | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
FR2795963A1 (en) * | 1999-07-08 | 2001-01-12 | Pasteur Merieux Serums Vacc | New polynucleotides are useful as vaccines for humans |
WO2001007055A1 (en) * | 1999-07-27 | 2001-02-01 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Covalently closed immunostimulating nucleic acid molecule |
WO2001012804A2 (en) * | 1999-08-13 | 2001-02-22 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
WO2001015726A2 (en) * | 1999-08-27 | 2001-03-08 | Inex Pharmaceuticals Corp. | Compositions for stimulating cytokine secretion and inducing an immune response |
US6200592B1 (en) | 1996-10-25 | 2001-03-13 | 3M Innovative Properties Company | Immine response modifier compounds for treatment of TH2 mediated and related diseases |
US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
WO2000061151A3 (en) * | 1999-04-12 | 2001-04-26 | Us Health | Oligodeoxynucleotide and its use to induce an immune response |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO2001051500A1 (en) * | 2000-01-14 | 2001-07-19 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2001022990A3 (en) * | 1999-09-27 | 2001-10-04 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
WO2001076642A1 (en) * | 2000-04-07 | 2001-10-18 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
WO2002002172A1 (en) * | 2000-06-30 | 2002-01-10 | Univ Jefferson | Dna palindrome - oligoguanylic acid compositions and uses thereof |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO2002055090A1 (en) * | 2001-01-12 | 2002-07-18 | Amato Pharmaceutical Products,Ltd. | Preventives for microbial infections |
JP2002522510A (en) * | 1998-08-10 | 2002-07-23 | アクウィラ・バイオファーマシューティカルズ・インコーポレイテッド | Compositions of CPG and saponin adjuvant and methods thereof |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
WO2002060476A2 (en) * | 2001-01-31 | 2002-08-08 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Tumor vaccine |
US6444233B1 (en) | 1998-05-19 | 2002-09-03 | Research Development Foundation | Triterpene compositions and methods for use thereof |
EP1259264A2 (en) * | 2000-02-23 | 2002-11-27 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
WO2003014316A2 (en) | 2001-08-07 | 2003-02-20 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
JP2003510282A (en) * | 1999-09-25 | 2003-03-18 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Immunostimulatory nucleic acids |
WO2003028656A2 (en) | 2001-10-03 | 2003-04-10 | Chiron Corporation | Adjuvant compositions |
WO2003030656A2 (en) | 2001-10-06 | 2003-04-17 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO2003066649A1 (en) * | 2002-02-04 | 2003-08-14 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
US6610661B1 (en) | 1996-10-11 | 2003-08-26 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
WO2003070909A2 (en) | 2002-02-20 | 2003-08-28 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
JP2003535907A (en) * | 2000-06-22 | 2003-12-02 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Method for promoting antibody-induced cell lysis and treating cancer |
EP1374894A2 (en) * | 1997-06-06 | 2004-01-02 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO2004011650A2 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
AU770464B2 (en) * | 1998-12-22 | 2004-02-19 | Seer Pharmaceuticals, Llc | Treatment of skin lesions |
WO2004016805A2 (en) | 2002-08-19 | 2004-02-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
WO2004031382A1 (en) * | 2002-10-02 | 2004-04-15 | Mochida Pharmaceutical Co., Ltd. | Novel method of constructing monoclonal antibody |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
EP1435987A1 (en) * | 2001-09-07 | 2004-07-14 | The Trustees of Boston University | Method and composition for treating immune complex associated disorders |
EP1005368A4 (en) * | 1997-03-10 | 2004-09-29 | Ottawa Health Research Inst | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
WO2004084938A1 (en) | 2003-03-24 | 2004-10-07 | Intercell Ag | Improved vaccines |
US6821957B2 (en) | 1997-05-20 | 2004-11-23 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
WO2005039634A1 (en) * | 2003-10-13 | 2005-05-06 | Glaxosmithkline Biologicals Sa | Vaccine compositions comprising an interleukin 18 and saponin adjuvant system |
EP1541170A1 (en) * | 1999-04-19 | 2005-06-15 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
US6943240B2 (en) | 2000-09-15 | 2005-09-13 | Coley Pharmaceuticals Gmbh | Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist |
EP1572122A2 (en) * | 2002-11-01 | 2005-09-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
JP2005532067A (en) * | 2002-07-03 | 2005-10-27 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Nucleic acid composition for stimulating immune response |
WO2005111057A2 (en) * | 2004-04-02 | 2005-11-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing il-10 responses |
AU2003203948B2 (en) * | 1997-09-05 | 2005-12-22 | The Regents Of The University Of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
US7001890B1 (en) | 1997-01-23 | 2006-02-21 | Coley Pharmaceutical Gmbh | Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |
EP1631576A2 (en) * | 2003-06-11 | 2006-03-08 | Hybridon, Inc. | Stabilized immunomodulatory oligonucleotides |
EP1688147A1 (en) * | 1999-09-27 | 2006-08-09 | Coley Pharmaceutical Group, Inc. | Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon |
WO2006086799A2 (en) | 2005-02-11 | 2006-08-17 | Novartis Vaccines And Diagnostics Inc. | Prion-specific peptide reagents |
WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
US7250403B2 (en) | 2000-03-10 | 2007-07-31 | Dynavax Technologies Corporation | Biodegradable immunomodulatory formulations and methods for use thereof |
US7255868B2 (en) | 2001-06-21 | 2007-08-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—I |
US7282476B2 (en) | 2001-08-24 | 2007-10-16 | University Of Victoria Innovation And Development Corporation | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
WO2007119815A1 (en) | 2006-04-14 | 2007-10-25 | Kyowa Hakko Kirin Co., Ltd. | Toll-like receptor 9 agonists |
US7378234B2 (en) | 2002-09-13 | 2008-05-27 | Intercell Ag | Method for isolating hepatitis C virus peptides |
EP1985702A2 (en) | 2000-12-08 | 2008-10-29 | Coley Pharmaceuticals GmbH | CPG-like nucleic acids and methods of use thereof |
EP1992635A1 (en) | 2002-12-23 | 2008-11-19 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US7479285B1 (en) | 1999-08-19 | 2009-01-20 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
US7507802B2 (en) * | 2002-05-22 | 2009-03-24 | Eyegene, Inc. | Immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides |
JP2009060909A (en) * | 1998-05-27 | 2009-03-26 | Cj Cheil Jedang Corp | Novel endonuclease of immunocyte, method for production thereof, and immunoadjuvant using the same |
US7514414B2 (en) | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
US7514415B2 (en) | 2002-08-01 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides |
US7517520B2 (en) | 2003-03-26 | 2009-04-14 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
EP2149583A1 (en) | 2004-09-24 | 2010-02-03 | Intercell AG | Modified VP1-capsid protein of parvovirus B19 |
EP2168597A1 (en) | 2001-07-26 | 2010-03-31 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
EP2179729A1 (en) | 2003-06-02 | 2010-04-28 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
US7723500B2 (en) | 1994-07-15 | 2010-05-25 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7727712B2 (en) | 2000-03-10 | 2010-06-01 | Dynavax Technologies Corporation | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
WO2010067286A2 (en) | 2008-12-09 | 2010-06-17 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE |
WO2010067262A1 (en) | 2008-12-09 | 2010-06-17 | Pfizer Inc. | Immunostimulatory oligonucleotides |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
US7790189B2 (en) * | 2003-05-15 | 2010-09-07 | Mitsui Sugar Co., Ltd. | Immunostimulating agents |
EP2258390A1 (en) | 2002-08-30 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Improved bacterial outer membrane vesicles |
EP2258716A2 (en) | 2002-11-22 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Multiple variants of meningococcal protein NMB1870 |
EP2263687A1 (en) | 2002-12-27 | 2010-12-22 | Novartis Vaccines&Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
EP2263688A1 (en) | 2001-06-20 | 2010-12-22 | Novartis AG | Neisseria meningitidis combination vaccines |
US7858588B2 (en) | 2001-05-21 | 2010-12-28 | Intercell Ag | Immunostimulatory oligodeoxynucleic molecules |
US7871984B2 (en) * | 2003-04-23 | 2011-01-18 | Yukio Sato | Methylated CpG polynucleotide |
WO2011007961A2 (en) | 2009-07-17 | 2011-01-20 | Industry Academic Cooperation Foundation, Hallym University | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes |
EP2277896A1 (en) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
EP2279746A2 (en) | 2002-11-15 | 2011-02-02 | Novartis Vaccines and Diagnostics S.r.l. | Surface proteins in neisseria meningitidis |
WO2011013034A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
EP2286792A1 (en) | 1999-02-26 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with an adsorbent surface, comprising a microdroplet emulsion |
US7901907B2 (en) | 1996-01-04 | 2011-03-08 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Process for production of Helicobacter pylori bacterioferritin |
WO2011027257A2 (en) | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
EP2327719A1 (en) | 2001-09-06 | 2011-06-01 | Novartis Vaccines and Diagnostics S.r.l. | Hybrid and tandem expression of neisserial proteins |
WO2011077309A2 (en) | 2009-12-22 | 2011-06-30 | Pfizer Vaccines Llc | Vaccine compositions |
WO2011109422A2 (en) | 2010-03-02 | 2011-09-09 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
WO2011148356A1 (en) | 2010-05-28 | 2011-12-01 | Coley Pharmaceutical Group, Inc. | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules |
US8071371B2 (en) | 2003-02-26 | 2011-12-06 | Humabs Llc | Monoclonal antibody production by EBV transformation of B cells |
WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
US8101345B1 (en) | 2005-03-25 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Proinflammatory nucleic acids |
EP2433647A2 (en) | 2005-01-27 | 2012-03-28 | Children's Hospital & Research Center at Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US8222225B2 (en) | 2008-05-21 | 2012-07-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating pneumoconiosis with oligodeoxynucleotides |
US8226957B2 (en) | 2000-03-10 | 2012-07-24 | Dynavax Technologies Corporation | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
EP2545931A1 (en) | 2004-03-19 | 2013-01-16 | Herbs Spring, LLC | Herbal therapy for the treatment of food allergy |
US8372413B2 (en) | 2000-12-27 | 2013-02-12 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
US8394390B2 (en) | 1999-10-29 | 2013-03-12 | Novartis Ag | Neisserial antigenic peptides |
EP2631245A1 (en) | 2008-03-10 | 2013-08-28 | Children's Hospital & Research Center at Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
US8552165B2 (en) | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
WO2013162828A1 (en) | 2012-04-27 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing |
US8574564B2 (en) | 2005-12-14 | 2013-11-05 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
WO2013164754A2 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
US8592566B2 (en) | 2006-05-31 | 2013-11-26 | Toray Industries, Inc. | Immunostimulatory oligonucleotides and use thereof in pharmaceuticals |
US20140056931A1 (en) * | 2002-09-05 | 2014-02-27 | University Of South Florida | Genetic adjuvants for immunotherapy |
US20140086982A1 (en) * | 2012-09-25 | 2014-03-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
US8691209B2 (en) | 2001-09-14 | 2014-04-08 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US8834900B2 (en) | 2001-08-17 | 2014-09-16 | University Of Iowa Research Foundation | Combination motif immune stimulatory oligonucleotides with improved activity |
DE102013004595A1 (en) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV vaccines |
WO2014173814A1 (en) | 2013-04-22 | 2014-10-30 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies against human csf-1r and tlr9 agonist |
US8895521B2 (en) | 2004-05-06 | 2014-11-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the treatment of uveitis |
WO2014201245A1 (en) | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
US8916161B2 (en) | 2005-06-14 | 2014-12-23 | Sophiris Bio Inc. | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
US8993542B2 (en) | 2008-01-25 | 2015-03-31 | Chimerix Inc. | Methods of treating viral infections |
US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
WO2015110941A2 (en) | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
WO2015124614A1 (en) | 2014-02-18 | 2015-08-27 | Mologen Ag | Covalently closed non-coding immunomodulatory dna construct |
US9205143B2 (en) | 2009-04-30 | 2015-12-08 | Coley Pharmaceutical Group Inc. | Pneumococcal vaccine and uses thereof |
US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
US9364531B2 (en) | 2010-12-30 | 2016-06-14 | Intervet Inc. | Immunostimulatory oligodeoxynucleotides |
WO2016113644A1 (en) | 2015-01-15 | 2016-07-21 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US9404126B2 (en) | 2006-06-12 | 2016-08-02 | Kuros Biosciences Ag | Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages |
EP3067048A1 (en) | 2007-12-07 | 2016-09-14 | Novartis Ag | Compositions for inducing immune responses |
KR20160113332A (en) | 2010-12-23 | 2016-09-28 | 몰로젠 아게 | Non-coding immunomodulatory dna construct |
WO2016183371A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for the treatment or prevention of ischemic tissue damage |
US9539217B2 (en) | 2013-04-03 | 2017-01-10 | Allertein Therapeutics, Llc | Nanoparticle compositions |
US9549980B2 (en) | 2007-04-19 | 2017-01-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating necrotizing enterocolitis by administering nuclear oligomerization domain-2 agonists,TLR9 agonists and TLR4 antagonists |
US9549914B2 (en) | 2014-04-03 | 2017-01-24 | The Johns Hopkins University | Treatment of human cytomegalovirus by modulating Wnt |
WO2017013548A1 (en) | 2015-07-21 | 2017-01-26 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
US9617547B2 (en) | 2012-07-13 | 2017-04-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
WO2017085586A1 (en) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US9695211B2 (en) | 2008-12-02 | 2017-07-04 | Wave Life Sciences Japan, Inc. | Method for the synthesis of phosphorus atom modified nucleic acids |
EP3095460A4 (en) * | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
US9809824B2 (en) | 2004-12-13 | 2017-11-07 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
US9982257B2 (en) | 2012-07-13 | 2018-05-29 | Wave Life Sciences Ltd. | Chiral control |
EP3327028A1 (en) | 2010-03-30 | 2018-05-30 | Children's Hospital & Research Center at Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
WO2018134693A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
US10160969B2 (en) | 2014-01-16 | 2018-12-25 | Wave Life Sciences Ltd. | Chiral design |
US10172848B2 (en) | 2010-12-22 | 2019-01-08 | University of Pittsburgh—Of the Commonwealth Systems of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
WO2019066571A2 (en) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and uses thereof |
US10300083B2 (en) | 2010-09-24 | 2019-05-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
US10682365B2 (en) | 2014-12-31 | 2020-06-16 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
EP3689375A1 (en) | 2013-05-15 | 2020-08-05 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
WO2020208502A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
WO2021154745A1 (en) | 2020-01-27 | 2021-08-05 | Oregon State University | Gonorrhea subunit vaccine |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CN114450014A (en) * | 2019-06-14 | 2022-05-06 | G科技生物有限责任公司 | Activated lymphocytic cells and methods of using the same for treating cancer and infectious disorders |
WO2022097010A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
US11434292B2 (en) | 2018-05-23 | 2022-09-06 | Pfizer Inc. | Antibodies specific for CD3 and uses thereof |
US11498968B2 (en) | 2016-12-22 | 2022-11-15 | Hoffmann-La Roche Inc. | Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment |
US11512133B2 (en) | 2013-09-12 | 2022-11-29 | Hoffmann-La Roche Inc. | Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1 |
WO2022249107A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2022249106A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US11578331B2 (en) | 2015-09-09 | 2023-02-14 | Gilead Sciences, Inc. | Combination comprising immunostimulatory oligonucleotides |
US11583581B2 (en) | 2015-09-21 | 2023-02-21 | Gilead Sciences, Inc. | Methods of treating a retroviral infection |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
US11633503B2 (en) | 2009-01-08 | 2023-04-25 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US11883535B2 (en) | 2013-12-03 | 2024-01-30 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
US11957788B2 (en) | 2014-06-04 | 2024-04-16 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
Families Citing this family (637)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6498147B2 (en) * | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
CA2110946A1 (en) * | 1992-12-09 | 1994-06-10 | Elazar Rabbani | Induction of immunocompatibility by nucleic acid |
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US20030109469A1 (en) * | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US7034007B1 (en) * | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
EP0879284B1 (en) * | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20040147022A1 (en) * | 1996-06-06 | 2004-07-29 | Baker Brenda F. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
US20040171031A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US20050119470A1 (en) * | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
ATE235890T1 (en) * | 1997-01-30 | 2003-04-15 | Chiron Corp | USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE DEFENSE |
US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US20030104044A1 (en) * | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
DE69841002D1 (en) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Highly effective encapsulation of nucleic acids in lipid vesicles |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
ATE408422T1 (en) * | 1997-07-03 | 2008-10-15 | Donald E Macfarlane | METHOD FOR INHIBITING IMMUNO-STIMULATORY RESPONSE ASSOCIATED WITH DNA |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
DE69931377T2 (en) * | 1998-09-18 | 2007-05-10 | Dynavax Technologies Corp., Berkeley | PROCESS FOR TREATING IG-E ASSOCIATED DISEASES AND COMPOSITIONS FOR USE THEREOF IN THESE METHODS |
US6423493B1 (en) * | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
DE60023300T2 (en) * | 1999-06-29 | 2006-07-06 | Glaxosmithkline Biologicals S.A. | USE OF CPG AS ADJUVANS FOR HIV PULP |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
US20050226890A1 (en) * | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
US20050249794A1 (en) * | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
AU3108001A (en) * | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
US6552006B2 (en) | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
WO2001062092A1 (en) * | 2000-02-25 | 2001-08-30 | Thomas Jefferson University | Formulations and methods for using the same to elicit an immune response |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
CA2407942A1 (en) * | 2000-05-01 | 2001-11-08 | Hybridon, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
US6696064B2 (en) * | 2000-06-20 | 2004-02-24 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy |
AU2001276831A1 (en) | 2000-06-22 | 2002-01-02 | Rxkinetix, Inc. | Delivery vehicle composition and methods for delivering antigens and other drugs |
CN1196788C (en) * | 2000-06-23 | 2005-04-13 | 惠氏控股有限公司 | Assembly of wild-type and chimeric influenza virus-like particles (VLPS) |
KR100917101B1 (en) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | Flexible metal laminate and production method thereof |
WO2006033665A1 (en) * | 2004-03-16 | 2006-03-30 | Inist Inc. | Tat-based vaccine compositions and methods of making and using same |
WO2005090392A1 (en) * | 2004-03-16 | 2005-09-29 | Inist Inc. | Tat-based tolerogen compositions and methods of making and using same |
IL154557A0 (en) * | 2000-08-25 | 2003-09-17 | Yeda Res & Dev | Methods of treatment or prevention of autoimmune diseases with cpg-containing polynucleotide |
WO2002026757A2 (en) * | 2000-09-26 | 2002-04-04 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
WO2006091720A2 (en) * | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
US20070128229A1 (en) * | 2002-04-12 | 2007-06-07 | Wyeth | Surface proteins of Streptococcus pyogenes |
IL158328A0 (en) * | 2001-04-13 | 2004-05-12 | Wyeth Corp | Surface proteins of streptococcus pyogenes |
MXPA03009415A (en) | 2001-04-16 | 2004-01-29 | Wyeth Corp | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof. |
US7034140B2 (en) * | 2001-04-24 | 2006-04-25 | E.I. Du Pont De Nemours And Company | Genes involved in isoprenoid compound production |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
JP4370161B2 (en) * | 2001-06-29 | 2009-11-25 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | HCVE1E2 vaccine composition |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
AU2002318944A1 (en) * | 2001-08-01 | 2003-02-17 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
EP1501359A4 (en) * | 2001-08-03 | 2007-04-18 | Celldex Therapeutics Inc | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
AU2002361468A1 (en) * | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
JP2005501550A (en) * | 2001-08-30 | 2005-01-20 | スリーエム イノベイティブ プロパティズ カンパニー | Maturation of plasmacytoid dendritic cells using immune response modifier molecules |
WO2003024480A2 (en) * | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
BR0213097A (en) * | 2001-10-05 | 2005-02-01 | Coley Pharm Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
EP1434602B1 (en) * | 2001-10-06 | 2014-12-17 | Merial Limited | CpG plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein D |
MX339524B (en) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. |
US20030139364A1 (en) * | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
WO2003039595A2 (en) * | 2001-11-07 | 2003-05-15 | Inex Pharmaceuticals Corporation | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
CA2466530A1 (en) * | 2001-11-09 | 2003-05-15 | Medigene Aktiengesellschaft | Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell |
DE60230340D1 (en) * | 2001-11-16 | 2009-01-22 | 3M Innovative Properties Co | N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use |
US7179798B2 (en) * | 2001-11-16 | 2007-02-20 | Russell R. Roby | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
US20050250716A1 (en) * | 2001-12-07 | 2005-11-10 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
CA2365732A1 (en) * | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
EP1467755A1 (en) * | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
ES2541132T3 (en) * | 2002-02-22 | 2015-07-16 | Meda Ab | Method to reduce and treat UV-B-induced immunosuppression |
US6923958B2 (en) * | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
CN100593544C (en) * | 2002-03-15 | 2010-03-10 | 惠氏控股有限公司 | Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
AU2003218181A1 (en) * | 2002-03-15 | 2003-09-29 | Multicell Immunotherapeutics, Inc. | Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response |
EP3006043B1 (en) * | 2002-04-04 | 2019-05-29 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
US20030224013A1 (en) * | 2002-04-19 | 2003-12-04 | Cole Garry T. | Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein |
US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
US20040009944A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
US20040009943A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
WO2004042001A2 (en) * | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
CA2388049A1 (en) * | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US20040009949A1 (en) * | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
BR0311995A (en) * | 2002-06-20 | 2005-04-05 | Cytos Biotechnology Ag | Virus-like particles packaged for use as adjuvants: Method of preparation and use |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
WO2004007743A2 (en) * | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
US20060270620A1 (en) * | 2002-07-23 | 2006-11-30 | University Of South Florida | Method of Enhancing Therapeutic Effect of Nucleic Acids |
EP1545597B1 (en) | 2002-08-15 | 2010-11-17 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
EP1537208A1 (en) * | 2002-09-13 | 2005-06-08 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
US7301554B2 (en) * | 2002-09-20 | 2007-11-27 | Ricoh Company, Ltd. | Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method |
ATE492288T1 (en) | 2002-10-11 | 2011-01-15 | Novartis Vaccines & Diagnostic | POLYPEPTIDE VACCINES FOR BROAD PROTECTION AGAINST HYPERVIRULENT MENINGOCOCCAL LINES |
CA2503457A1 (en) * | 2002-10-25 | 2004-05-06 | University Of Connecticut Health Center | Apparatus and method for immunotherapy of a cancer through controlled cell lysis |
ZA200503511B (en) * | 2002-10-29 | 2006-10-25 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
WO2004044139A2 (en) * | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
US8039443B2 (en) * | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
DK1569696T3 (en) * | 2002-11-21 | 2010-11-15 | Bayhill Therapeutics Inc | Methods and Immunomodulatory Nucleic Acid Preparations for the Prevention and Treatment of Diseases |
US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
US20050124565A1 (en) * | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US20040213808A1 (en) * | 2002-12-11 | 2004-10-28 | Michael Lieberman | Recombinant vaccine against flavivirus infection |
WO2004053452A2 (en) * | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
AU2003287324A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
US7625872B2 (en) * | 2002-12-23 | 2009-12-01 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
CA2511538C (en) * | 2002-12-30 | 2013-11-26 | 3M Innovative Properties Company | Immunostimulatory combinations |
JP4827726B2 (en) | 2003-01-30 | 2011-11-30 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Injectable vaccine against multiple meningococcal serogroups |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
US7375180B2 (en) * | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
EP1601756B1 (en) | 2003-02-20 | 2010-12-15 | University of Connecticut Health Center | Methods for the preparation of alpha (2) macroglobulin-antigenic molecule complexes |
EP1599726A4 (en) * | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | Selective modulation of tlr-mediated biological activity |
CA2517528A1 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of uv-induced epidermal neoplasia |
CN100439386C (en) * | 2003-03-05 | 2008-12-03 | 长春华普生物技术有限公司 | Deoxyoligonucleotide containing CpG single strand for strengthening immunological effect of Protein vaccine |
CA2518282C (en) * | 2003-03-13 | 2012-11-06 | 3M Innovative Properties Company | Methods of improving skin quality |
AU2004220465A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
AU2004225480A1 (en) * | 2003-03-26 | 2004-10-14 | Multicell Immunotherapeutics, Inc. | Selected RNA motifs to include cell death and/or apoptosis |
US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
AU2004226605A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
CA2522379C (en) | 2003-04-10 | 2012-10-23 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
US20040202720A1 (en) * | 2003-04-10 | 2004-10-14 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
WO2004094614A2 (en) | 2003-04-21 | 2004-11-04 | Archemix Corp. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US20050250106A1 (en) * | 2003-04-24 | 2005-11-10 | David Epstein | Gene knock-down by intracellular expression of aptamers |
NZ543343A (en) * | 2003-04-25 | 2008-03-28 | Novartis Vaccines & Diagnostic | Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof |
US20040214851A1 (en) * | 2003-04-28 | 2004-10-28 | 3M Innovative Properties Company | Compositions and methods for induction of opioid receptors |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
US7803386B2 (en) | 2003-06-05 | 2010-09-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
BRPI0411514A (en) * | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | small molecule toll-like receptor antagonists |
AU2004255470B2 (en) * | 2003-07-10 | 2010-08-19 | Cytos Biotechnology Ag | Packaged virus-like particles |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
CA2534042A1 (en) * | 2003-07-31 | 2005-02-10 | 3M Innovative Properties Company | Compositions for encapsulation and controlled release |
CA2534313C (en) * | 2003-08-05 | 2013-03-19 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
TW200510412A (en) * | 2003-08-12 | 2005-03-16 | 3M Innovative Properties Co | Oxime substituted imidazo-containing compounds |
US20050065136A1 (en) * | 2003-08-13 | 2005-03-24 | Roby Russell R. | Methods and compositions for the treatment of infertility using dilute hormone solutions |
US8071652B2 (en) * | 2003-08-21 | 2011-12-06 | The Board Of Regents Of The University Of Texas System | Method of treating irritable bowel syndrome |
US8961477B2 (en) * | 2003-08-25 | 2015-02-24 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
JP2007504145A (en) * | 2003-08-25 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Immunostimulatory combinations and treatments |
CA2536136C (en) * | 2003-08-27 | 2012-10-30 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
JP2007504172A (en) * | 2003-09-02 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Methods for treatment of mucosa related symptoms |
JP2007504269A (en) * | 2003-09-05 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Method for treating CD5 + B cell lymphoma |
CA2538794C (en) | 2003-09-12 | 2016-04-19 | Antigenics, Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
CN103357002A (en) | 2003-10-02 | 2013-10-23 | 诺华疫苗和诊断有限公司 | Liquid vaccines for multiple meningococcal serogroups |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
JP5043435B2 (en) * | 2003-10-03 | 2012-10-10 | スリーエム イノベイティブ プロパティズ カンパニー | Alkoxy substituted imidazoquinolines |
US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
EP1675614A2 (en) * | 2003-10-11 | 2006-07-05 | Inex Pharmaceuticals Corp. | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
CN101454451A (en) * | 2003-10-30 | 2009-06-10 | 科勒制药有限公司 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
AU2004285575A1 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
CN1906193A (en) | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | Oxime substituted imidazo ring compounds |
AU2004291122A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
AR046781A1 (en) * | 2003-11-25 | 2005-12-21 | 3M Innovative Properties Co | IMIDAZOQUINOLINE DERIVATIVES. PHARMACEUTICAL COMPOSITIONS. |
US20050287118A1 (en) * | 2003-11-26 | 2005-12-29 | Epitomics, Inc. | Bacterial plasmid with immunological adjuvant function and uses thereof |
US20050277127A1 (en) * | 2003-11-26 | 2005-12-15 | Epitomics, Inc. | High-throughput method of DNA immunogen preparation and immunization |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
EP1689361A4 (en) * | 2003-12-02 | 2009-06-17 | 3M Innovative Properties Co | Therapeutic combinations and methods including irm compounds |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
PT1701968E (en) | 2003-12-17 | 2015-09-11 | Wyeth Llc | Immunogenic peptide carrier conjugates and methods of producing same |
AR047062A1 (en) | 2003-12-17 | 2006-01-04 | Wyeth Corp | CONJUGATED CARRIERS OF BETA IMMUNOGENIC PEPTIDES AND METHODS FOR PRODUCERS |
JP4817599B2 (en) * | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | Immune activity enhancer and method for enhancing immune activity using the same |
WO2005066170A1 (en) * | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
WO2005066169A2 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
US20050239735A1 (en) * | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
KR100558851B1 (en) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | Modified CpG oligodeoxynucleotide with improved immunoregulatory function |
WO2005072290A2 (en) * | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
EP1720568A2 (en) | 2004-02-19 | 2006-11-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
DK1716234T3 (en) * | 2004-02-20 | 2014-01-20 | Mologen Ag | Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic immune stimulation in humans and higher animals |
US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
EP1722815A1 (en) | 2004-03-09 | 2006-11-22 | Chiron Corporation | Influenza virus vaccines |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
WO2005094531A2 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
US20050260755A1 (en) * | 2004-04-06 | 2005-11-24 | Isis Pharmaceuticals, Inc. | Sequential delivery of oligomeric compounds |
US20050239757A1 (en) * | 2004-04-21 | 2005-10-27 | Roby Russell R | Hormone treatment of macular degeneration |
WO2005105107A2 (en) * | 2004-04-21 | 2005-11-10 | Roby Russell R | Hormone treatment of multiple sclerosis |
US7579450B2 (en) * | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
JP2008505857A (en) * | 2004-04-28 | 2008-02-28 | スリーエム イノベイティブ プロパティズ カンパニー | Compositions and methods for mucosal vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
RU2379052C2 (en) | 2004-04-30 | 2010-01-20 | Чирон С.Р.Л. | Meningococcal conjugate vaccination |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
CN1296378C (en) * | 2004-05-17 | 2007-01-24 | 中国人民解放军第三军医大学 | CpG-N ODN gene sequence with high immunological activity CpG-S ODN and antagonism CpG-N ODN and use thereof |
EP1766094A4 (en) * | 2004-05-18 | 2009-11-25 | Vical Inc | Influenza virus vaccine composition and method of use |
KR20070029708A (en) | 2004-05-21 | 2007-03-14 | 와이어쓰 | Altered fibronectin-binding protein of staphylococcus aureus |
WO2006078294A2 (en) | 2004-05-21 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Alphavirus vectors for respiratory pathogen vaccines |
US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
US20080154210A1 (en) | 2004-05-28 | 2008-06-26 | Oryxe | Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
AU2005252662B2 (en) * | 2004-06-03 | 2011-08-18 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
CA2567789A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
US8017779B2 (en) * | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US7915281B2 (en) * | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
US7897609B2 (en) * | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
WO2006009826A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
US7482158B2 (en) * | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
US20060025390A1 (en) * | 2004-07-28 | 2006-02-02 | Roby Russell R | Treatment of hormone allergy and related symptoms and disorders |
JP2008508320A (en) | 2004-07-29 | 2008-03-21 | カイロン コーポレイション | Immunogenic composition against gram positive bacteria such as STREPTOCOCCUSAGALACTIAE |
ES2534288T3 (en) | 2004-08-03 | 2015-04-21 | Innate Pharma | Therapeutic compositions against cancer that target 4Ig-B7-H3 |
US20060045886A1 (en) * | 2004-08-27 | 2006-03-02 | Kedl Ross M | HIV immunostimulatory compositions |
US20090270443A1 (en) * | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
US7884086B2 (en) * | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
JP2008000001A (en) * | 2004-09-30 | 2008-01-10 | Osaka Univ | Immune stimulating oligonucleotide and use in pharmaceutical |
CN102302773B (en) | 2004-10-06 | 2014-05-14 | 米迪缪尼有限公司 | Refrigerator-temperature stable influenza vaccine compositions |
EP2808384B1 (en) | 2004-10-08 | 2017-12-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Modulation of replicative fitness by using less frequently used synonymous codons |
JP2008515928A (en) * | 2004-10-08 | 2008-05-15 | スリーエム イノベイティブ プロパティズ カンパニー | Adjuvants for DNA vaccines |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
EP2298341A3 (en) | 2004-10-21 | 2011-07-13 | Wyeth LLC | Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
EP3034089A1 (en) | 2004-11-02 | 2016-06-22 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US7332324B2 (en) | 2004-12-03 | 2008-02-19 | University Of Toledo | Attenuated vaccine useful for immunizations against Coccidioides spp. infections |
WO2006063072A2 (en) * | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
WO2006073760A2 (en) | 2004-12-17 | 2006-07-13 | Dana-Farber Cancer Institute, Inc. | Regulation of mink in thymocytes and t lymphocytes |
US20060153844A1 (en) * | 2004-12-29 | 2006-07-13 | Thomas Kundig | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
WO2006074003A2 (en) * | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS |
JP2008526765A (en) | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | Treatment of skin metastases |
US8034938B2 (en) | 2004-12-30 | 2011-10-11 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
EP1841777B1 (en) * | 2005-01-28 | 2015-09-30 | Kwon, Hyung-Joo | Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
WO2006084251A2 (en) * | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
JP2008530113A (en) | 2005-02-11 | 2008-08-07 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Oxime and hydroxyramine substituted imidazo [4,5-c] ring compounds and methods |
EP1858920B1 (en) | 2005-02-18 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
SG164344A1 (en) | 2005-02-18 | 2010-09-29 | Novartis Vaccines & Diagnostics Srl | Immunogens from uropathogenic escherichia coli |
JP2008531018A (en) * | 2005-02-24 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Immunostimulatory oligonucleotide |
CA2600036A1 (en) | 2005-03-04 | 2006-09-14 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
US7943636B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
EP2842559A3 (en) * | 2005-04-08 | 2015-03-18 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
JP2008535859A (en) * | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Methods for treating asthma exacerbated by infection |
KR101730748B1 (en) | 2005-04-08 | 2017-04-26 | 와이어쓰 엘엘씨 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
WO2006110831A2 (en) | 2005-04-12 | 2006-10-19 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
WO2006113528A2 (en) | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
JP2008539252A (en) * | 2005-04-25 | 2008-11-13 | スリーエム イノベイティブ プロパティズ カンパニー | Immune activation composition |
WO2006116458A2 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
CA2613442C (en) | 2005-06-30 | 2016-08-23 | Archemix Corp. | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
ES2435531T3 (en) | 2005-07-01 | 2013-12-20 | Index Pharmaceuticals Ab | Modulation of steroid responsiveness |
PT2269622E (en) | 2005-07-01 | 2014-03-20 | Index Pharmaceuticals Ab | Cpg oligonucleotides used for enhancing steroid activity in a steroid dependent patient |
US20090117132A1 (en) * | 2005-07-07 | 2009-05-07 | Pfizer, Inc. | Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment |
US20080206276A1 (en) | 2005-07-08 | 2008-08-28 | Michael Otto | Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections |
EP2614709A1 (en) | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
WO2007012285A1 (en) * | 2005-07-28 | 2007-02-01 | Changchun Huapu Biotechnology Co., Ltd. | Viral infection resistent single strand deoxynucleosides |
US20090306177A1 (en) * | 2005-09-16 | 2009-12-10 | Coley Pharmaceutical Gmbh | Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (Sirna) by Nucleotide Modification |
WO2007088423A2 (en) * | 2005-09-16 | 2007-08-09 | Coley Pharmaceutical Gmbh | Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone |
US20070081972A1 (en) * | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
WO2007047749A1 (en) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
EP1940472A1 (en) | 2005-10-28 | 2008-07-09 | Index Pharmaceuticals AB | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
EP1945252B1 (en) | 2005-11-04 | 2013-05-29 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene |
PT1951299E (en) | 2005-11-04 | 2012-02-28 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
CA2628206A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
JP2009514839A (en) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Adjuvant influenza vaccine containing cytokine inducer |
CN102864152B (en) * | 2005-11-07 | 2015-11-18 | 艾德拉药物股份有限公司 | Comprise the immunostimulatory properties of the compound based on oligonucleotide of modified immunostimulating dinucleotides |
WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
KR20080072934A (en) | 2005-11-25 | 2008-08-07 | 콜리 파마슈티칼 게엠베하 | Immunostimulatory oligoribonucleotides |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
JP6087041B2 (en) | 2006-01-27 | 2017-03-08 | ノバルティス アーゲー | Influenza virus vaccine containing hemagglutinin and matrix protein |
EP1991678B2 (en) * | 2006-02-15 | 2020-07-15 | Rechtsanwalt Thomas Beck | Compositions and methods for oligonucleotide formulations |
WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
EP2441469A1 (en) | 2006-03-14 | 2012-04-18 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
CA2646539A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
CA2646891A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
WO2007110776A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
EP2382988A1 (en) | 2006-03-31 | 2011-11-02 | Novartis AG | Combined mucosal and parenteral immunization against HIV |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
US20080026986A1 (en) * | 2006-06-05 | 2008-01-31 | Rong-Fu Wang | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
ATE522541T1 (en) | 2006-06-09 | 2011-09-15 | Novartis Ag | BACTERIAL ADHESIN CONFORMERS |
EP2029169A2 (en) | 2006-06-20 | 2009-03-04 | Transgene S.A. | Recombinant viral vaccine |
WO2008094183A2 (en) * | 2006-07-11 | 2008-08-07 | University Of Connecticut | Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination |
US8153116B2 (en) | 2006-07-11 | 2012-04-10 | University Of Connecticut | Use of conditional plasmodium strains lacking an essential gene in malaria vaccination |
US7906506B2 (en) * | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
ES2536401T3 (en) | 2006-09-11 | 2015-05-25 | Novartis Ag | Making vaccines against influenza viruses without using eggs |
MX2009003398A (en) * | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
DE102006050655A1 (en) * | 2006-10-24 | 2008-04-30 | Halmon Beheer B.V. | Pharmaceutical composition useful for treating allergic diseases comprises RNA and an allergen |
BRPI0718182A2 (en) * | 2006-10-26 | 2014-02-25 | Coley Pharm Gmbh | OLIGORRIBONUCLEOTIDS AND THEIR USES. |
ES2663080T3 (en) | 2006-11-01 | 2018-04-11 | Ventana Medical Systems, Inc. | Haptenos, haptens conjugates, compositions thereof and method for their preparation and use |
US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
EP2094849B1 (en) | 2006-11-09 | 2014-01-08 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
EP2094279B1 (en) * | 2006-11-15 | 2015-01-07 | Eli Lilly and Company | Methods and compositions for treating influenza |
ES2480491T3 (en) | 2006-12-06 | 2014-07-28 | Novartis Ag | Vaccines including four influenza virus strains antigen |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
AR064642A1 (en) | 2006-12-22 | 2009-04-15 | Wyeth Corp | POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
JP5596980B2 (en) | 2007-02-28 | 2014-10-01 | アメリカ合衆国 | Brachyury polypeptides and methods of use |
CA2683752A1 (en) * | 2007-04-13 | 2008-10-23 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
EP2377952A1 (en) | 2007-04-26 | 2011-10-19 | Ludwig Institute For Cancer Research | Methods for diagnosing and treating astrocytomas |
WO2008134077A1 (en) * | 2007-04-30 | 2008-11-06 | Archemix Corp. | Metabolic profile directed aptamer medicinal chemistry |
CA2687441A1 (en) * | 2007-05-17 | 2008-11-27 | Coley Pharmaceutical Group, Inc. | Class a oligonucleotides with immunostimulatory potency |
PT2170353E (en) * | 2007-05-18 | 2015-09-16 | Adiutide Pharmaceuticals Gmbh | Phosphate-modified oligonucleotide analogs with immunostimulatory activity |
ES2731432T3 (en) | 2007-05-23 | 2019-11-15 | Ventana Med Syst Inc | Polymeric transporters for immunohistochemistry and in situ hybridization |
CA2687632C (en) * | 2007-05-24 | 2013-01-15 | Glaxosmithkline Biologicals S.A. | Lyophilised antigen composition |
BRPI0813866A2 (en) | 2007-06-27 | 2015-01-06 | Novartis Ag | VACCINES AGAINST INFLUENCE WITH LOW ADDITIVE CONTENT |
GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
US7879812B2 (en) | 2007-08-06 | 2011-02-01 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides and methods of use therefor |
EP2187961A2 (en) * | 2007-08-21 | 2010-05-26 | Dynavax Technologies Corporation | Composition and methods of making and using influenza proteins |
ES2561483T3 (en) | 2007-09-12 | 2016-02-26 | Glaxosmithkline Biologicals Sa | GAS57 mutant antigens and GAS57 antibodies |
CN101820908A (en) * | 2007-10-09 | 2010-09-01 | 科利制药公司 | The immune stimulatory oligonucleotide analogs that comprises modified sugar moieties |
US20110014231A1 (en) * | 2007-11-05 | 2011-01-20 | Mor Research Applications Ltd | Anti-measles cancer immunotherapy |
WO2009062112A2 (en) | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
KR101773114B1 (en) | 2007-12-21 | 2017-08-30 | 노파르티스 아게 | Mutant forms of streptolysin o |
CN101981182A (en) * | 2007-12-21 | 2011-02-23 | 惠氏有限责任公司 | Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use therof |
CA2710534C (en) * | 2008-01-31 | 2018-09-04 | Curevac Gmbh | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
ES2532946T3 (en) | 2008-02-21 | 2015-04-06 | Novartis Ag | Meningococcal PUfH polypeptides |
JP5518041B2 (en) | 2008-03-18 | 2014-06-11 | ノバルティス アーゲー | Improvements in the preparation of influenza virus vaccine antigens |
CA2724418A1 (en) * | 2008-05-15 | 2009-11-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
WO2009149013A2 (en) | 2008-06-05 | 2009-12-10 | Ventana Medical Systems, Inc. | Compositions comprising nanomaterials and method for using such compositions for histochemical processes |
MX2010014358A (en) | 2008-06-20 | 2011-07-04 | Wyeth Llc | Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains. |
NZ727616A (en) | 2008-06-27 | 2018-06-29 | Zoetis Services Llc | Novel adjuvant compositions |
TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
US20110136897A1 (en) * | 2008-08-14 | 2011-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders |
US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
EP2331127A2 (en) | 2008-09-18 | 2011-06-15 | Novartis AG | Vaccine adjuvant combinations |
US8658350B2 (en) | 2008-09-22 | 2014-02-25 | Oregon Health & Science University | Methods for detecting Mycobacterium tuberculosis disease |
EP2344522B1 (en) | 2008-10-16 | 2016-01-27 | The University of Saskatchewan | Combination adjuvant formulation |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
NO2356135T3 (en) * | 2008-11-05 | 2018-03-24 | ||
US8329188B2 (en) * | 2008-11-12 | 2012-12-11 | Theraclone Sciences, Inc. | Human M2e peptide immunogens |
CN102307477B (en) | 2009-01-05 | 2015-07-29 | 埃皮托吉尼西斯股份有限公司 | Adjunvant composition and using method |
US8465751B2 (en) | 2009-01-12 | 2013-06-18 | Novartis Ag | Cna—B domain antigens in vaccines against gram positive bacteria |
WO2010099472A2 (en) | 2009-02-27 | 2010-09-02 | The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services | Spanx-b polypeptides and their use |
EP3549602A1 (en) | 2009-03-06 | 2019-10-09 | GlaxoSmithKline Biologicals S.A. | Chlamydia antigens |
DK2411043T3 (en) | 2009-03-23 | 2013-10-21 | Pin Pharma Inc | TREATMENT OF CANCER WITH IMMUNOSTIMULATORY HIV TAT DERIVATE POLYPEPTIDES |
CN104548082A (en) | 2009-03-24 | 2015-04-29 | 诺华股份有限公司 | Adjuvanting meningococcal factor H binding protein |
CA3033133C (en) | 2009-03-25 | 2021-11-09 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
EP2413951A4 (en) | 2009-04-03 | 2015-05-20 | Univ Duke | Formulation for inducing broadly reactive neutralizing anti-hiv antibodies |
WO2010115118A2 (en) | 2009-04-03 | 2010-10-07 | Antigenics, Inc. | Methods for preparing and using multichaperone-antigen complexes |
SI2510947T1 (en) | 2009-04-14 | 2016-05-31 | Glaxosmithkline Biologicals S.A. | Compositions for immunising against Staphylococcus aureus |
US20110223201A1 (en) * | 2009-04-21 | 2011-09-15 | Selecta Biosciences, Inc. | Immunonanotherapeutics Providing a Th1-Biased Response |
AU2010254550B2 (en) | 2009-05-27 | 2015-10-15 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents |
CA2765364C (en) | 2009-06-15 | 2015-05-26 | National University Of Singapore | Influenza vaccine, composition, and methods of use |
MX2012000044A (en) | 2009-06-22 | 2012-01-30 | Wyeth Llc | Immunogenic compositions of staphylococcus aureus antigens. |
AU2010301043B2 (en) | 2009-06-22 | 2014-01-09 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
BR112012001666A2 (en) | 2009-07-15 | 2019-09-24 | Novartis Ag | rsv f protein compositions and methods for making the same |
JP2012532626A (en) | 2009-07-16 | 2012-12-20 | ノバルティス アーゲー | Detoxified Escherichia coli immunogen |
US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
CA2770762A1 (en) * | 2009-08-18 | 2011-02-24 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
EP2470554B1 (en) | 2009-08-26 | 2017-06-28 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
AU2010288239B2 (en) | 2009-08-27 | 2014-01-16 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
CN102596240B (en) | 2009-08-27 | 2015-02-04 | 诺华股份有限公司 | Hybrid polypeptides including meningococcal fHBP sequences |
WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
CN102724988B (en) | 2009-09-30 | 2014-09-10 | 诺华股份有限公司 | Expression of meningococcal fHBP polypeptides |
CA2779798C (en) | 2009-09-30 | 2019-03-19 | Novartis Ag | Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides |
AU2010305273B2 (en) | 2009-10-07 | 2016-09-29 | Uvic Industry Partnerships Inc. | Vaccines comprising heat-sensitive transgenes |
US9181306B2 (en) | 2009-10-16 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
MX2012004850A (en) | 2009-10-27 | 2012-05-22 | Novartis Ag | Modified meningococcal fhbp polypeptides. |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
EP2501397B1 (en) | 2009-11-20 | 2017-10-04 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
JP2013521002A (en) | 2010-03-05 | 2013-06-10 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | Induced dendritic cell composition and use thereof |
WO2011112599A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary. Department Of Health & Human Services | Immunogenic pote peptides and methods of use |
EP2547357A1 (en) | 2010-03-18 | 2013-01-23 | Novartis AG | Adjuvanted vaccines for serogroup b meningococcus |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
JP2013529894A (en) | 2010-04-07 | 2013-07-25 | ノバルティス アーゲー | Method for generating parvovirus B19 virus-like particles |
EP2558069A1 (en) | 2010-04-13 | 2013-02-20 | Novartis AG | Benzonapthyridine compositions and uses thereof |
HUE037227T2 (en) | 2010-05-14 | 2018-08-28 | Univ Oregon Health & Science | Recombinant HCMV and RHCMV vectors and uses thereof |
AU2011258156B2 (en) | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
KR20130121699A (en) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | Interactive hybrid asynchronous computer game infrastructure |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
CN102933229A (en) | 2010-06-04 | 2013-02-13 | 惠氏有限责任公司 | Vaccine formulations |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
WO2012006293A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
WO2012025873A2 (en) | 2010-08-23 | 2012-03-01 | Wyeth Llc | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
PE20140173A1 (en) | 2010-09-10 | 2014-02-20 | Wyeth Llc | NON-LIPIDED VARIANTS OF NEISSERIA MENINGITIDIS ANTIGENS ORF2086 |
EP2616545B1 (en) | 2010-09-14 | 2018-08-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
EP2468866A1 (en) * | 2010-12-21 | 2012-06-27 | Index Pharmaceuticals AB | Biologically active oligonucleotides capable of modulating the immune system |
BR112013016153A2 (en) | 2010-12-22 | 2017-07-11 | Wyeth Llc | stable immunogenic compositions of staphylococcus aureus antigens |
UA118537C2 (en) | 2010-12-22 | 2019-02-11 | Байєр Інтеллектуал Проперті Гмбх | Enhanced immune response in bovine species |
WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
SI2667892T1 (en) | 2011-01-26 | 2019-05-31 | Glaxosmithkline Biologicals Sa | Rsv immunization regimen |
AU2012214148A1 (en) | 2011-02-11 | 2013-08-29 | Baxter Healthcare S.A. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
US9452212B2 (en) | 2011-04-14 | 2016-09-27 | Dynavax Technologies Corporation | Methods and compositions for eliciting an immune response against hepatitis B virus |
US20120288515A1 (en) | 2011-04-27 | 2012-11-15 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
ES2651143T3 (en) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | RS prefusion F antigens |
FR2975600B1 (en) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | AGENTS FOR THE TREATMENT OF TUMORS |
TR201808393T4 (en) * | 2011-05-26 | 2018-07-23 | Intervet Int Bv | Immunostimulatory oligodeoxynucleotides. |
AU2012262021B2 (en) | 2011-06-01 | 2016-07-28 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
WO2012167046A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
BR112013031039B1 (en) | 2011-06-03 | 2020-04-28 | 3M Innovative Properties Co | hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate |
JP6460789B2 (en) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker |
US8697085B2 (en) | 2011-06-17 | 2014-04-15 | University Of Tennessee Research Foundation | Group A Streptococcus multivalent vaccine |
CA2839995A1 (en) | 2011-06-20 | 2012-12-27 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for h1n1 influenza |
ITMI20111182A1 (en) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | VACCINE FOR CORONAVIRUS CANINO |
WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
EP2729168A2 (en) | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
WO2013007703A1 (en) * | 2011-07-08 | 2013-01-17 | Universität Zürich | CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS |
US9149541B2 (en) | 2011-07-08 | 2015-10-06 | Novartis Ag | Tyrosine ligation process |
US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
WO2013016460A1 (en) | 2011-07-25 | 2013-01-31 | Novartis Ag | Compositions and methods for assessing functional immunogenicity of parvovirus vaccines |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
US20140348865A1 (en) | 2011-09-12 | 2014-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. | Immunogens based on an hiv-1 v1v2 site-of-vulnerability |
CN103917245B (en) | 2011-09-14 | 2017-06-06 | 葛兰素史密丝克莱恩生物有限公司 | Method for preparing glycoprotein glycoconjugate |
WO2013038385A2 (en) | 2011-09-14 | 2013-03-21 | Novartis Ag | Escherichia coli vaccine combination |
US20140234360A1 (en) | 2011-09-30 | 2014-08-21 | The United States of America, as represented by the Secretary, Dept.of Health and Human Services | Influenza vaccine |
CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
WO2013059493A1 (en) | 2011-10-20 | 2013-04-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
CN104080479B (en) | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | Carrier molecules including spr0096 and spr2021 antigen |
RU2014127714A (en) | 2011-12-08 | 2016-01-27 | Новартис Аг | TOXIN VACCINE Clostridium difficile |
EP2804613A4 (en) | 2012-01-16 | 2015-12-09 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
RU2653756C2 (en) | 2012-02-07 | 2018-05-14 | Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Computationally optimized broadly reactive antigens for h3n2 viruses |
JP6175452B2 (en) | 2012-02-13 | 2017-08-02 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Computationally optimized reactive antigen for human and avian H5N1 influenza |
CA2865028A1 (en) | 2012-02-24 | 2013-08-29 | Novartis Ag | Pilus proteins and compositions |
SG10201602558UA (en) | 2012-03-09 | 2016-05-30 | Pfizer | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (en) | 2012-03-09 | 2017-04-12 | فايزر انك | Neisseria meningitidis compositions and methods thereof |
CA2866185C (en) | 2012-03-23 | 2021-04-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pathogenic phlebovirus isolates and compositions and methods of use |
US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
BR112014026812A8 (en) | 2012-04-26 | 2022-10-04 | Novartis Ag | ANTIGENS AND ANTIGEN COMBINATIONS |
MX2014014067A (en) | 2012-05-22 | 2015-02-04 | Novartis Ag | Meningococcus serogroup x conjugate. |
IN2014DN09618A (en) | 2012-05-23 | 2015-07-31 | Us Sec Dep Of Health And Human Services | |
US9427476B2 (en) | 2012-05-24 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent meningococcal conjugates and methods for preparing conjugates |
US9957969B2 (en) | 2012-06-19 | 2018-05-01 | Volvo Lastvagnar Ab | Device for controlling a gas flow, an exhaust aftertreatment system and a system for propelling a vehicle |
WO2013192144A2 (en) | 2012-06-19 | 2013-12-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Rift valley fever virus replicon particles and use thereof |
KR102057217B1 (en) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
WO2014005958A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Immunogenic compositions and uses thereof |
CA2879443A1 (en) | 2012-07-19 | 2014-01-23 | Zoetis Llc | Bovine influenza virus compositions |
JP6575950B2 (en) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Mutations with resistance to Bruton tyrosine kinase (Btk) inhibitors |
AU2013295770A1 (en) | 2012-07-27 | 2015-01-29 | Zoetis Services Llc | Tick toxin compositions |
ES2700824T3 (en) | 2012-08-16 | 2019-02-19 | Pfizer | Glucoconjugation procedures and compositions |
WO2014037124A1 (en) | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
EP3400960A1 (en) | 2012-09-18 | 2018-11-14 | GlaxoSmithKline Biologicals S.A. | Outer membrane vesicles |
JP2015535829A (en) | 2012-09-21 | 2015-12-17 | マッケーナ、エリザベス | Naturally occurring CpG oligonucleotide compositions and therapeutic applications thereof |
CN104717977A (en) | 2012-10-03 | 2015-06-17 | 诺华股份有限公司 | Immunogenic composition |
CN111329989A (en) | 2012-11-02 | 2020-06-26 | 药品循环有限责任公司 | TEC family kinase inhibitor adjuvant therapy |
WO2014074785A1 (en) | 2012-11-08 | 2014-05-15 | Ludwig Institute For Cancer Research Ltd. | Methods of predicting outcome and treating breast cancer |
KR20140075201A (en) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
KR20140075196A (en) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
TWI465241B (en) | 2012-12-19 | 2014-12-21 | Ind Tech Res Inst | Use of an extract of juniperus chinensis or lignan for manufacturing a medicament for inhibiting angiogenesis |
EP3363806B1 (en) | 2012-12-20 | 2022-11-16 | Pfizer Inc. | Glycoconjugation process |
CA2936092A1 (en) | 2013-01-23 | 2014-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized hepatitis b core polypeptide |
WO2014124228A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
EP2968510B1 (en) | 2013-03-14 | 2019-10-09 | President and Fellows of Harvard College | Nanoparticle-based compositions |
EP2983703A1 (en) | 2013-03-15 | 2016-02-17 | Zoetis Services LLC | Cross-protection of bovines against b. trehalosi infection by a multi-valent vaccine |
US20160083698A1 (en) | 2013-04-19 | 2016-03-24 | The Regents Of The University Of California | Lone star virus |
CN103550783A (en) * | 2013-04-27 | 2014-02-05 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Nucleic acid drug targeting delivery system and preparation method thereof |
CN112263675B (en) * | 2013-07-19 | 2024-02-27 | 财团法人卫生研究院 | CpG oligodeoxynucleotides, immune compositions comprising same and methods of preparing compositions and stimulating immune responses by same |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US9919029B2 (en) | 2013-07-26 | 2018-03-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
WO2015042423A2 (en) | 2013-09-19 | 2015-03-26 | Zoetis Llc | Vaccine |
US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
EP3052517B1 (en) | 2013-09-30 | 2023-07-19 | Triad National Security, LLC | Mosaic conserved region hiv immunogenic polypeptides |
WO2015051245A1 (en) | 2013-10-04 | 2015-04-09 | Pin Pharma, Inc. | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment |
BR112016008806A2 (en) | 2013-11-01 | 2017-10-03 | Pfizer | VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
WO2015078856A1 (en) | 2013-11-28 | 2015-06-04 | Bavarian Nordic A/S | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
WO2015089469A1 (en) | 2013-12-13 | 2015-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multi-epitope tarp peptide vaccine and uses thereof |
US11708411B2 (en) | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
CA2935722A1 (en) | 2014-01-21 | 2015-07-30 | Immune Design Corp. | Compositions for use in the treatment of allergic conditions |
RU2743793C1 (en) | 2014-01-21 | 2021-02-26 | Пфайзер Инк. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
MX371454B (en) | 2014-01-21 | 2020-01-29 | Pfizer | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof. |
WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
JP2017505792A (en) | 2014-02-14 | 2017-02-23 | ファイザー・インク | Immunogenic glycoprotein conjugates |
US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
US10155950B2 (en) * | 2014-02-28 | 2018-12-18 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
CN106535930A (en) | 2014-03-11 | 2017-03-22 | 明尼苏达大学董事会 | Porcine epidemic diarrhea virus vaccines and methods of use thereof |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
ES2769647T3 (en) | 2014-03-26 | 2020-06-26 | Glaxosmithkline Biologicals Sa | Mutant Staphylococcal Antigens |
WO2015164798A1 (en) | 2014-04-25 | 2015-10-29 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
CA2950158A1 (en) * | 2014-05-23 | 2015-11-26 | Gregory CAUCHON | Coating method and materials |
CA2986096A1 (en) | 2014-05-30 | 2015-12-03 | Sanofi Pasteur Inc. | Expression and conformational analysis of engineered influenza hemagglutinin |
US20150374815A1 (en) | 2014-06-25 | 2015-12-31 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
MX2017000630A (en) | 2014-07-15 | 2017-04-27 | Immune Design Corp | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector. |
US20170275287A1 (en) | 2014-08-22 | 2017-09-28 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
CA2963931A1 (en) | 2014-10-06 | 2016-04-14 | Exicure, Inc. | Anti-tnf compounds |
US20160129097A1 (en) * | 2014-11-06 | 2016-05-12 | Jeremy Delk | Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit |
JP2017537619A (en) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes |
WO2016103531A1 (en) * | 2014-12-26 | 2016-06-30 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Use of nucleic acid-polysaccharide complexes having immunopotentiating activity as anti-tumor drug |
SG11201705737RA (en) | 2015-01-16 | 2017-08-30 | Zoetis Services Llc | Foot-and-mouth disease vaccine |
WO2016131048A1 (en) | 2015-02-13 | 2016-08-18 | Icahn School Of Medicine At Mount Sinai | Rna containing compositions and methods of their use |
BR112017017460A2 (en) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | neisseria meningitidis compositions and methods thereof |
MX2017011648A (en) | 2015-03-12 | 2017-11-02 | Zoetis Services Llc | Pyolysin methods and compositions. |
MY182282A (en) | 2015-05-04 | 2021-01-18 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
WO2016180852A1 (en) | 2015-05-12 | 2016-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preparing antigen-specific t cells from an umbilical cord blood sample |
JP6925980B2 (en) | 2015-05-13 | 2021-08-25 | アジェナス インコーポレイテッド | Vaccines for the treatment and prevention of cancer |
AU2016270979B2 (en) | 2015-06-02 | 2020-11-12 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
US11305002B2 (en) | 2015-06-09 | 2022-04-19 | The Board Of Regents Of The University Of Oklahoma | Compositions and treatments for Haemophilus influenzae |
EP3307878B1 (en) | 2015-06-10 | 2021-08-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Processes for production and purification of nucleic acid-containing compositions |
EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
JP6840332B2 (en) * | 2015-07-09 | 2021-03-10 | 国立研究開発法人物質・材料研究機構 | Immunostimulatory oligonucleotide complex |
BR112018002107A2 (en) | 2015-07-31 | 2018-09-25 | Bayer Animal Health Gmbh | boosted immune response in swine species |
HUE060545T2 (en) | 2015-08-14 | 2023-03-28 | Zoetis Services Llc | Mycoplasma bovis compositions |
WO2017040885A1 (en) | 2015-09-03 | 2017-03-09 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
WO2017048807A1 (en) | 2015-09-17 | 2017-03-23 | Jrx Biotechnology, Inc. | Approaches for improving skin hydration or moisturization |
WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
US10548970B2 (en) | 2015-10-05 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human rotavirus G9P[6] strain and use as a vaccine |
JP7171433B2 (en) | 2015-10-30 | 2022-11-15 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Compositions and methods for treatment of HER-2 expressing solid tumors |
US10596248B2 (en) | 2015-12-09 | 2020-03-24 | Jingang Medicine (Australia) Pty Ltd | Immunomodulating composition for treatment |
EP3402878A1 (en) | 2016-01-11 | 2018-11-21 | Zoetis Services LLC | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
CA3009928A1 (en) | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
WO2017189448A1 (en) | 2016-04-25 | 2017-11-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bivalent immunogenic conjugate for malaria and typhoid |
US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
WO2017210215A1 (en) | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
MA45165A (en) | 2016-06-02 | 2019-04-10 | Sanofi Pasteur Inc | MODIFIED INFLUENZATIGENIC POLYPEPTIDES AND ASSOCIATED IMMUNOGENIC COMPOSITIONS |
SG10201913650WA (en) | 2016-06-03 | 2020-03-30 | Sanofi Pasteur Inc | Modification of engineered influenza hemagglutinin polypeptides |
CA3026807A1 (en) | 2016-06-13 | 2017-12-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays |
US11191822B2 (en) | 2016-06-22 | 2021-12-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
EP3269385A1 (en) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
US10632185B2 (en) | 2016-07-08 | 2020-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric west nile/zika viruses and methods of use |
WO2018009604A1 (en) | 2016-07-08 | 2018-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric dengue/zika viruses live-attenuated zika virus vaccines |
CN109862908B (en) | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
MX2019001341A (en) | 2016-08-05 | 2019-07-04 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
US10182146B2 (en) * | 2016-08-22 | 2019-01-15 | Nice Ltd. | System and method for dynamic redundant call recording |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US10172933B2 (en) | 2016-10-31 | 2019-01-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Mosaic vaccines for serotype a foot-and-mouth disease virus |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CN110225757A (en) | 2017-01-31 | 2019-09-10 | 默沙东公司 | By the method for S. pneumoniae serotypes 19F production capsular polysaccharide protein conjugate |
US11623945B2 (en) | 2017-02-06 | 2023-04-11 | The United States Of America, As Represented By The Secretary Of Agriculture | Immunostimulating compositions and uses therefore |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
US10525119B2 (en) | 2017-03-31 | 2020-01-07 | Boston Medical Center Corporation | Methods and compositions using highly conserved pneumococcal surface proteins |
US20200115324A1 (en) | 2017-06-11 | 2020-04-16 | Molecular Express, Inc. | Methods and compositions for substance use disorder vaccine formulations and uses thereof |
US11612647B2 (en) | 2017-06-23 | 2023-03-28 | University Of Maryland, Baltimore | Immunogenic compositions |
WO2019018744A1 (en) | 2017-07-21 | 2019-01-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neisseria meningitidis immunogenic compositions |
KR20200051004A (en) | 2017-09-07 | 2020-05-12 | 머크 샤프 앤드 돔 코포레이션 | Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates |
WO2019048631A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Hnf4a sarna compositions and methods of use |
EP3703745B1 (en) | 2017-11-04 | 2024-04-10 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
CA3084436A1 (en) | 2017-12-06 | 2019-07-18 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
WO2019126197A1 (en) | 2017-12-18 | 2019-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacterial polysaccharide-conjugated carrier proteins and use thereof |
KR20200101954A (en) | 2017-12-19 | 2020-08-28 | 메사추세츠 인스티튜트 오브 테크놀로지 | Antigen-adjuvant coupling reagents and methods of use |
WO2019143955A1 (en) | 2018-01-22 | 2019-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly protective inactivated influenza virus vaccine |
CA3034912A1 (en) | 2018-02-28 | 2019-08-28 | Pfizer Inc. | Il-15 variants and uses thereof |
CN112118847A (en) * | 2018-03-02 | 2020-12-22 | 伊莱西奥治疗有限公司 | Compounds comprising mutated KRAS sequences and lipids and uses thereof |
WO2019191257A1 (en) | 2018-03-28 | 2019-10-03 | Sanofi Pasteur Inc. | Methods of generating broadly protective vaccine compositions comprising hemagglutinin |
JP2021519599A (en) | 2018-04-03 | 2021-08-12 | サノフイSanofi | Antigenic OSPA polypeptide |
CN112512565A (en) | 2018-04-03 | 2021-03-16 | 赛诺菲 | Antigenic influenza-ferritin polypeptides |
CN112512566A (en) | 2018-04-03 | 2021-03-16 | 赛诺菲 | Antigenic epstein-barr virus polypeptides |
WO2019195316A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Ferritin proteins |
MX2020010199A (en) | 2018-04-03 | 2021-01-08 | Sanofi Sa | Antigenic respiratory syncytial virus polypeptides. |
EP3796983A2 (en) | 2018-05-23 | 2021-03-31 | Pfizer Inc. | Antibodies specific for gucy2c and uses thereof |
EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
CN110004150B (en) * | 2018-08-01 | 2023-03-10 | 中国农业科学院兰州兽医研究所 | CpG oligonucleotide sequence with immune enhancement activity and application thereof |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
EP3891170A4 (en) | 2018-12-04 | 2022-12-07 | The Rockefeller University | Hiv vaccine immunogens |
US20220023413A1 (en) | 2018-12-12 | 2022-01-27 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins |
CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
EP3894429B1 (en) | 2018-12-14 | 2024-02-21 | University of Georgia Research Foundation, Inc. | Crimean-congo hemorrhagic fever virus replicon particles and use thereof |
AU2019401535B2 (en) | 2018-12-19 | 2023-12-14 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
WO2020205986A1 (en) | 2019-04-02 | 2020-10-08 | Sanofi | Antigenic multimeric respiratory syncytial virus polypeptides |
US20220241321A1 (en) * | 2019-05-10 | 2022-08-04 | Microbio (Shanghai) Co., Ltd. | Dimeric cpg oligonucleotides for use in modulating immune responses |
WO2021015987A1 (en) | 2019-07-19 | 2021-01-28 | Merck Sharp & Dohme Corp. | Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof |
WO2021021778A1 (en) | 2019-07-30 | 2021-02-04 | Phibro Animal Health Corporation | A composition for mucosal administration to avians |
WO2021021729A1 (en) | 2019-07-31 | 2021-02-04 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
JP2022545181A (en) | 2019-08-30 | 2022-10-26 | ユニバーシティ オブ ロチェスター | Septin inhibitors for cancer therapy |
CN110646557A (en) * | 2019-10-12 | 2020-01-03 | 北京航空航天大学 | Urine metabolic marker of glioblastoma patient carrying IDH gene mutation and application thereof |
EP4051696A1 (en) | 2019-11-01 | 2022-09-07 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
US20230039456A1 (en) | 2019-12-17 | 2023-02-09 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Live attenuated leishmania parasite vaccines with enhanced safety characteristics |
IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies specific for cd47, pd-l1, and uses thereof |
CN115209916A (en) | 2020-02-13 | 2022-10-18 | 伊利诺伊大学理事会 | Vaccines and methods for detecting and preventing filariasis |
MX2022010350A (en) | 2020-02-23 | 2022-09-19 | Pfizer | Compositions and methods thereof. |
JP2023515829A (en) | 2020-02-28 | 2023-04-14 | サノフィ パスツール インコーポレイテッド | High-dose influenza vaccine for pediatric subjects |
US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
US20230226218A1 (en) | 2020-05-11 | 2023-07-20 | Erytech Pharma | Red Cell Extracellular Vesicles (RCEVs) Containing Cargoes and Methods of Use and Production Thereof |
TW202216779A (en) | 2020-07-17 | 2022-05-01 | 美商輝瑞股份有限公司 | Therapeutic antibodies and their uses |
US20230321212A1 (en) | 2020-08-26 | 2023-10-12 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
EP4213874A1 (en) | 2020-09-17 | 2023-07-26 | Neovacs | Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders |
WO2022066965A2 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting sox2 antigens |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
JP2023546615A (en) | 2020-10-27 | 2023-11-06 | ファイザー・インク | E. coli composition and method thereof |
WO2022101745A2 (en) | 2020-11-10 | 2022-05-19 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
US20240115674A1 (en) | 2021-02-03 | 2024-04-11 | The Board Of Trustees Of The University Of Illinois | Vaccine and methods for preventing filariasis and dirofilariasis |
KR20240004764A (en) | 2021-04-30 | 2024-01-11 | 칼리버 임뮤노쎄라퓨틱스, 인크. | Oncolytic viruses for modified MHC expression |
WO2022261251A1 (en) | 2021-06-08 | 2022-12-15 | Glyde Bio Inc. | Immunogenic compositions comprising tumour-associated antigen |
EP4104830A1 (en) | 2021-06-16 | 2022-12-21 | Burghardt Wittig | Sequential innate and adaptive immune modulation for cancer treatment |
CA3226187A1 (en) | 2021-07-16 | 2023-01-19 | The Board Of Trustees Of The University Of Illinois | Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs |
WO2023018817A1 (en) | 2021-08-11 | 2023-02-16 | Sanofi Pasteur Inc. | Truncated influenza neuraminidase and methods of using the same |
CA3233926A1 (en) | 2021-10-08 | 2023-04-13 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
TW202346593A (en) | 2021-11-05 | 2023-12-01 | 法商賽諾菲公司 | Respiratory syncytial virus rna vaccine |
WO2023081798A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
AR127808A1 (en) | 2021-11-30 | 2024-02-28 | Sanofi Pasteur Inc | VACCINES AGAINST THE HUMAN METAPNEUMOVIRUS |
WO2023102388A1 (en) | 2021-11-30 | 2023-06-08 | Sanofi Pasteur Inc. | Human metapneumovirus viral vector-based vaccines |
WO2023111262A1 (en) | 2021-12-17 | 2023-06-22 | Sanofi | Lyme disease rna vaccine |
WO2023144206A1 (en) | 2022-01-27 | 2023-08-03 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
WO2023177579A1 (en) | 2022-03-14 | 2023-09-21 | Sanofi Pasteur Inc. | Machine-learning techniques in protein design for vaccine generation |
WO2023201109A1 (en) | 2022-04-15 | 2023-10-19 | Yale University | Exatecan formulation |
WO2023214082A2 (en) | 2022-05-06 | 2023-11-09 | Sanofi | Signal sequences for nucleic acid vaccines |
WO2023218322A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002555A1 (en) * | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
Family Cites Families (523)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2010A (en) * | 1841-03-18 | Machine foe | ||
US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US2005A (en) * | 1841-03-16 | Improvement in the manner of constructing molds for casting butt-hinges | ||
US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
US3521637A (en) * | 1967-11-28 | 1970-07-28 | Nelson J Waterbury | Tampon or similar sanitary napkin containing vitamin a |
US3627874A (en) | 1969-07-16 | 1971-12-14 | Merck & Co Inc | Vaccine preparation |
US3761585A (en) | 1971-04-05 | 1973-09-25 | Beecham Group Ltd | Vaccines containing modified allergenic material |
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
DE2643213C2 (en) * | 1976-09-25 | 1985-02-21 | Bayer Ag, 5090 Leverkusen | Process for attenuating or inactivating microorganisms |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
DE3280400D1 (en) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | OLIGONUCLEOTIDES MEDICINE AND THEIR PRODUCTION METHOD. |
ES507187A0 (en) | 1981-11-16 | 1983-01-01 | Union Ind Y Agro Ganader S A U | PROCEDURE FOR OBTAINING AN ADDITIONAL HUMANIZED MILK OF NUCLEOTIDES FOR CHILD FEEDING. |
US5766920A (en) * | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
SE8205892D0 (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF |
US4452775A (en) * | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
SE8405493D0 (en) | 1984-11-01 | 1984-11-01 | Bror Morein | IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS |
US5308626A (en) * | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
DE3775783D1 (en) | 1986-01-14 | 1992-02-20 | Nederlanden Staat | METHOD FOR PRODUCING IMMUNOLOGICAL COMPLEXES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. |
US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5059519A (en) | 1986-07-01 | 1991-10-22 | University Of Massachusetts Medical School | Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases |
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
ES2007350A6 (en) | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
CA1339596C (en) | 1987-08-07 | 1997-12-23 | New England Medical Center Hospitals, Inc. | Viral expression inhibitors |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5112605A (en) * | 1989-03-17 | 1992-05-12 | Genentech, Inc. | Temporal gamma-interferon administration for allergies |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5629158A (en) * | 1989-03-22 | 1997-05-13 | Cemu Bitecknik Ab | Solid phase diagnosis of medical conditions |
US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
US5399676A (en) * | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5786189A (en) | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
US5457189A (en) | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
CA2084987C (en) | 1990-06-11 | 2007-02-13 | Larry Gold | Nucleic acid ligands |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5245022A (en) * | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
DK0544713T3 (en) | 1990-08-16 | 1997-09-29 | Isis Pharmaceuticals Inc | Oligonucleutides for modulating the effects of cytomegalovirus infections |
US6042838A (en) * | 1991-02-15 | 2000-03-28 | Uab Research Foundation | immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA) |
WO1992016192A1 (en) * | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
CA2106386A1 (en) | 1991-04-18 | 1992-10-19 | Barbara C. F. Chu | Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences |
US5498410A (en) * | 1991-04-22 | 1996-03-12 | Gleich; Gerald J. | Method for the treatment of eosinophil-associated conditions with anionic polymers |
US5681555A (en) | 1991-04-22 | 1997-10-28 | Gleich; Gerald J. | Method for the treatment of bronchial asthma by parenteral administration of anionic polymers |
WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
AU2169992A (en) | 1991-05-31 | 1993-01-08 | Genta Incorporated | Compositions and delivery systems for transdermal administration of neutral oligomers |
US5582986A (en) | 1991-06-14 | 1996-12-10 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
JPH07501525A (en) | 1991-11-15 | 1995-02-16 | テンプル ユニバーシティ ‐ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Treatment of melanoma with antisense oligonucleotides against the c-myb proto-oncogene |
WO1993010138A1 (en) | 1991-11-18 | 1993-05-27 | Tanox Biosystems, Inc. | Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
AU3610293A (en) | 1992-02-04 | 1993-09-01 | Chiron Viagene, Inc. | Hepatitis therapeutics |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US6498147B2 (en) | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
US5726518A (en) * | 1992-07-22 | 1998-03-10 | Nikon Corporation | Supporting device of relative moving element of vibration actuator or vibration motor |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
RU95104940A (en) | 1992-07-27 | 1997-01-10 | Хайбрайдон | Method of incorporation of alkylphosphonothioate or arylphosphonothioate internucleotide linkage in oligonucleotide, method of oligonucleotide synthesis, method of gene expression inhibition, treatment method |
US6107062A (en) * | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
WO1994004196A1 (en) | 1992-08-14 | 1994-03-03 | Imperial Cancer Research Technology Limited | Tumour therapy |
US5429199A (en) * | 1992-08-26 | 1995-07-04 | Kennametal Inc. | Cutting bit and cutting insert |
JPH08504570A (en) | 1992-10-05 | 1996-05-21 | ハイブライドン インコーポレイテッド | Therapeutic anti-HIV oligonucleotides and drugs |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
EP0692972B2 (en) * | 1993-04-02 | 2012-03-21 | AntiCancer, Inc. | Method for delivering beneficial compositions to hair follicles |
US5567604A (en) | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
SG54115A1 (en) * | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
US5840497A (en) | 1993-06-11 | 1998-11-24 | The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization | Method for specific silencing of genes by DNA methylation |
JP2798305B2 (en) * | 1993-06-23 | 1998-09-17 | ジェネシス ファーマ インコーポレイテッド | Antisense oligonucleotides and their use in human immunodeficiency virus infection |
AU688364B2 (en) | 1993-07-19 | 1998-03-12 | Gen-Probe Incorporated | Oligonucleotides with activity against human immunodeficiency virus |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
US6605708B1 (en) | 1993-07-28 | 2003-08-12 | Hybridon, Inc. | Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5985847A (en) | 1993-08-26 | 1999-11-16 | The Regents Of The University Of California | Devices for administration of naked polynucleotides which encode biologically active peptides |
JPH09501936A (en) | 1993-08-26 | 1997-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Methods, Compositions and Devices for Administering Naked Polynucleotides Encoding Bioactive Peptides |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US20030109469A1 (en) * | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
FR2711670B1 (en) * | 1993-10-22 | 1996-01-12 | Pasteur Institut | Nucleotide vector, composition containing it and vaccine for immunization against hepatitis. |
DE4338704A1 (en) * | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilized oligonucleotides and their use |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
JPH09506770A (en) | 1993-12-23 | 1997-07-08 | バイオグノステック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング | Antisense nucleic acid for preventing and treating diseases associated with the expression of c-erbB |
US5712384A (en) | 1994-01-05 | 1998-01-27 | Gene Shears Pty Ltd. | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
US5728518A (en) * | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
US5646126A (en) | 1994-02-28 | 1997-07-08 | Epoch Pharmaceuticals | Sterol modified oligonucleotide duplexes having anticancer activity |
CA2190121A1 (en) | 1994-03-15 | 1995-09-21 | Edith Mathiowitz | Polymeric gene delivery system |
US5596091A (en) * | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US5696248A (en) | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1996002560A1 (en) | 1994-07-18 | 1996-02-01 | University Of North Carolina At Chapel Hill | Oligonucleoside compounds and methods for inhibiting tumor growth, invasion and metastasis |
US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US6027726A (en) * | 1994-09-30 | 2000-02-22 | Inex Phamaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
EP1179340A3 (en) * | 1994-09-30 | 2003-05-07 | INEX Pharmaceutical Corp. | Compositions for the introduction of polyanionic materials into cells |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
WO1996012008A1 (en) | 1994-10-13 | 1996-04-25 | Merck & Co., Inc. | Synthesis of methylase-resistant genes |
US6630455B1 (en) | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
DE19502912A1 (en) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilized Oligonucleotides |
US5674483A (en) * | 1995-01-31 | 1997-10-07 | National Jewish Medical And Research Center | Treatment for diseases involving inflammation |
US5932556A (en) | 1995-09-17 | 1999-08-03 | Tam; Robert C | Methods and compositions for regulation of CD28 expression |
PL321711A1 (en) | 1995-02-09 | 1997-12-22 | Icn Pharmaceuticals | Methods of and compositions for controlling the cd28 expression |
GB9505438D0 (en) | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
US6096721A (en) * | 1995-04-13 | 2000-08-01 | Milkhaus Laboratory, Inc. | Method for treating mucositis by sublingual administration of DNA |
AU716486B2 (en) | 1995-04-13 | 2000-02-24 | Milkhaus Laboratory, Inc. | Methods for treating respiratory disease |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
US5858987A (en) * | 1995-05-05 | 1999-01-12 | Mitotix, Inc. | E6AP antisense constructs and methods of use |
EP0824588B1 (en) | 1995-05-11 | 2004-07-14 | Applied Research Systems ARS Holding N.V. | Il-6 activity inhibitor |
US5955059A (en) * | 1995-06-06 | 1999-09-21 | Trustees Of Boston University | Use of locally applied DNA fragments |
US5994315A (en) | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
US7034007B1 (en) * | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
JP4335310B2 (en) | 1995-06-07 | 2009-09-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Lipid-nucleic acid particles prepared through hydrophobic lipid-nucleic acid complex intermediates and use for gene transfer |
US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US6040296A (en) * | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
AU723325B2 (en) | 1995-06-23 | 2000-08-24 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
US6248720B1 (en) * | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
JPH11510142A (en) | 1995-07-21 | 1999-09-07 | ブラウン・ユニバーシティ・リサーチ・ファンデーション | Gene therapy using nucleic acid-loaded polymer microparticles |
US5968909A (en) | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
CN1172718C (en) | 1995-10-04 | 2004-10-27 | 依默耐克斯有限公司 | Dendritic cell stimulatory factor |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
EP0879284B1 (en) | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
SE9600647D0 (en) | 1996-02-21 | 1996-02-21 | Bror Morein | New use |
SE9600648D0 (en) * | 1996-02-21 | 1996-02-21 | Bror Morein | Receptor binding unit |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
US5843770A (en) | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
US6030955A (en) * | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
US6121247A (en) | 1996-03-29 | 2000-09-19 | The Johns Hopkins University | Therapy for allergic diseases |
US6184037B1 (en) | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
EP0961824A4 (en) | 1996-07-10 | 2003-01-29 | Immunex Corp | Method of activating dendritic cells |
DE69736692T2 (en) | 1996-07-16 | 2007-06-14 | Archibald James Mixson | Cationic vehicle: DNA complexes and their use in gene therapy |
US5854418A (en) | 1996-07-25 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof |
US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
DE19637223A1 (en) * | 1996-09-13 | 1998-04-09 | Beiersdorf Ag | Removable, self-adhesive device |
ATE292980T1 (en) * | 1996-10-11 | 2005-04-15 | Univ California | IMMUNO-STIMULATING OLIGONUCLEOTIDE CONJUGATES |
US6562345B1 (en) * | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
US20060002949A1 (en) * | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
SE9604296D0 (en) | 1996-11-22 | 1996-11-22 | Astra Ab | New pharmaceutical formulation of polypeptides |
FR2757876B1 (en) | 1996-12-27 | 1999-04-09 | Biovector Therapeutics Sa | CONJUGATES OF A PARTICULATE VECTOR AND OLIGONUCLEOTIDES, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
IL130192A0 (en) | 1996-12-27 | 2000-06-01 | Icn Pharmaceuticals | G-rich oligo aptamers and method of modulating an immune response |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US20030064945A1 (en) * | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
GB9702021D0 (en) | 1997-01-31 | 1997-03-19 | Imperial College | Medicaments |
US7517952B1 (en) * | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
WO1998037919A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
ATE441432T1 (en) * | 1997-03-10 | 2009-09-15 | Ottawa Hospital Res Inst | USE OF NON-METHYLATED CPG DINUCLEOTIDE IN COMBINATION WITH ALUMINUM AS ADJUVANTS |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
DE69841002D1 (en) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Highly effective encapsulation of nucleic acids in lipid vesicles |
US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
US20030104044A1 (en) * | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
JP2001526688A (en) | 1997-05-19 | 2001-12-18 | メルク エンド カンパニー インコーポレーテッド | Oligonucleotide adjuvant |
EP1003531B1 (en) * | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
CA2291483C (en) * | 1997-06-06 | 2012-09-18 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
ATE408422T1 (en) * | 1997-07-03 | 2008-10-15 | Donald E Macfarlane | METHOD FOR INHIBITING IMMUNO-STIMULATORY RESPONSE ASSOCIATED WITH DNA |
WO1999005303A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
EP1007657B1 (en) | 1997-08-19 | 2006-02-08 | Idera Pharmaceuticals, Inc. | Hiv-specific oligonucleotides and methods of their use |
EP1009413B1 (en) | 1997-09-05 | 2007-02-14 | The Regents Of The University Of California | Use of immunostimulatory oligonucleotides for preventing or treating asthma |
US6749856B1 (en) | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
CN1285753A (en) * | 1997-12-02 | 2001-02-28 | 鲍德杰克特疫苗公司 | Transdermal delivery of particulate vaccine compositions |
AU1656799A (en) | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
US7393630B2 (en) * | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
EP1041976B1 (en) | 1997-12-23 | 2006-04-05 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
US20050031638A1 (en) * | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
JPH11209289A (en) * | 1998-01-22 | 1999-08-03 | Taisho Pharmaceut Co Ltd | Mucosal immunity inducer |
JP4875799B2 (en) | 1998-02-25 | 2012-02-15 | アメリカ合衆国 | Use of skin permeation enhancers and barrier disintegrants to promote transdermal immune responses attracted by ADP-ribosylated exotoxins |
DK1388545T3 (en) * | 1998-03-12 | 2007-09-24 | Lucite Int Uk Ltd | polymer Composition |
ES2284247T3 (en) * | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | METHODS AND PRODUCTS TO STIMULATE THE IMMUNITY SYSTEM USING OLIGONUCLEOTIDES AND IMMUNOTHERAPEUTIC CYTOQUINS. |
WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
AU3764099A (en) | 1998-04-28 | 1999-11-16 | Tao Chen | Polyanionic polymers which enhance fusogenicity |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
IL139646A0 (en) * | 1998-05-14 | 2002-02-10 | Coley Pharm Group Inc | Methods for regulating hematopoiesis using cpg-oligonucleotides |
EP1733735B1 (en) | 1998-05-22 | 2017-03-22 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US6881561B1 (en) | 1998-05-27 | 2005-04-19 | Cheil Jedang Corporation | Endonuclease of immune cell, process for producing the same and immune adjuvant using the same |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
JP4627369B2 (en) | 1998-06-10 | 2011-02-09 | バイオグノスティック ゲゼルシャフト フュア バイオモレキュラー ダイアグノスティック ミット ベシュレンクテル ハフツング | How to stimulate the immune system |
AU748565B2 (en) * | 1998-06-23 | 2002-06-06 | Board Of Trustees Of The Leland Stanford Junior University | Adjuvant therapy |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
JP2002520038A (en) | 1998-07-20 | 2002-07-09 | アイネックス ファーマシューティカルズ コーポレイション | Liposome encapsulated nucleic acid complex |
WO2000006588A1 (en) | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
US20010034330A1 (en) | 1998-08-10 | 2001-10-25 | Charlotte Kensil | Innate immunity-stimulating compositions of CpG and saponin and methods thereof |
JP4620251B2 (en) * | 1998-08-10 | 2011-01-26 | アンチジェニックス・インコーポレイテッド | Composition of CPG and saponin adjuvant and method thereof |
CA2334044C (en) * | 1998-08-20 | 2014-03-25 | E.I. Du Pont De Nemours And Company | Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation |
CA2341338A1 (en) | 1998-09-03 | 2000-03-16 | Coley Pharmaceutical Gmbh | G-motif oligonucleotides and uses thereof |
US20020065236A1 (en) * | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
FR2783170B1 (en) * | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | IMMUNOSTIMULATING EMULSION |
EP1671646A3 (en) | 1998-09-18 | 2007-08-29 | Dynavax Technologies Corporation | Methods of treating IgE-associated disorders and compositions for use therein |
DE69931377T2 (en) | 1998-09-18 | 2007-05-10 | Dynavax Technologies Corp., Berkeley | PROCESS FOR TREATING IG-E ASSOCIATED DISEASES AND COMPOSITIONS FOR USE THEREOF IN THESE METHODS |
EP1119375A4 (en) | 1998-10-05 | 2005-02-02 | Regetns Of The University Of C | Methods and adjuvants for stimulating mucosal immunity |
AU6425999A (en) | 1998-10-09 | 2000-05-01 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
DE122007000087I1 (en) | 1998-10-16 | 2008-03-27 | Glaxosmithkline Biolog Sa | ADJUVANCY SYSTEMS AND VACCINES |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
AU2977500A (en) | 1999-02-02 | 2000-08-25 | Biocache Pharmaceuticals, Llc | Advanced antigen presentation platform |
US6887464B1 (en) | 1999-02-02 | 2005-05-03 | Biocache Pharmaceuticals, Inc. | Advanced antigen presentation platform |
JP2002536344A (en) | 1999-02-05 | 2002-10-29 | ジエンザイム コーポレイション | Use of cationic lipids to generate anti-tumor immunity |
US6207819B1 (en) | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
WO2000054803A2 (en) * | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
FR2790955B1 (en) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
BR0009163A (en) | 1999-03-19 | 2001-12-26 | Smithkline Beecham Biolog | Vaccine |
US6625426B2 (en) * | 1999-03-22 | 2003-09-23 | Ronald Baratono | Combined rear view mirror and telephone |
EP1176966B1 (en) * | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
AU4642600A (en) | 1999-04-15 | 2000-11-02 | Regents Of The University Of California, The | Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
BRPI0010612B8 (en) | 1999-04-19 | 2021-05-25 | Smithkline Beecham Biologicals S A | vaccines |
EP1177439B1 (en) | 1999-04-29 | 2004-09-08 | Coley Pharmaceutical GmbH | Screening for immunostimulatory dna functional modifiers |
US6737066B1 (en) * | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
CA2372960C (en) | 1999-05-06 | 2006-03-28 | The Immune Response Corporation | Hiv immunogenic compositions and methods |
WO2000075304A1 (en) | 1999-06-08 | 2000-12-14 | Aventis Pasteur | Immunostimulant oligonucleotide |
CA2412345A1 (en) | 1999-06-16 | 2000-12-21 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
DE60023300T2 (en) | 1999-06-29 | 2006-07-06 | Glaxosmithkline Biologicals S.A. | USE OF CPG AS ADJUVANS FOR HIV PULP |
GB9915204D0 (en) | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
FR2795963A1 (en) * | 1999-07-08 | 2001-01-12 | Pasteur Merieux Serums Vacc | New polynucleotides are useful as vaccines for humans |
DE19935756A1 (en) * | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Covalently closed nucleic acid molecule for immune stimulation |
EP2314693A3 (en) | 1999-08-13 | 2012-11-28 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
ATE419869T1 (en) | 1999-08-19 | 2009-01-15 | Dynavax Tech Corp | METHOD FOR MODULATING AN IMMUNE RESPONSE USING IMMUNSTIMULATIVE SEQUENCES AND COMPOSITIONS THEREOF |
US20050249794A1 (en) | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
US6395678B1 (en) * | 1999-09-01 | 2002-05-28 | Aero-Terra-Aqua Technologies Corporation | Bead and process for removing dissolved metal contaminants |
GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
AP1775A (en) * | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
MXPA02003059A (en) * | 1999-09-27 | 2002-09-30 | Univ Iowa Res Found | Methods related to immunostimulatory nucleic acid induced interferon. |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
EP1232267B1 (en) * | 1999-10-27 | 2013-03-20 | Novartis Vaccines and Diagnostics, Inc. | Activation of hcv-specific t cells |
US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
WO2001037869A1 (en) | 1999-11-19 | 2001-05-31 | Csl Limited | Vaccine compositions |
AU4139801A (en) * | 1999-12-06 | 2001-06-12 | Board Of Trustees Of The University Of Arkansas, The | Controlled delivery of antigens |
AU2593701A (en) | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
CA2397374A1 (en) | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
ATE378348T1 (en) * | 2000-01-14 | 2007-11-15 | Us Health | OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE |
AU3108001A (en) * | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
US6852705B2 (en) * | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
CA2398432C (en) | 2000-01-26 | 2012-06-19 | Hybridon, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
AT409085B (en) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES |
US6552006B2 (en) | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
KR100808348B1 (en) | 2000-01-31 | 2008-02-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccine for the prophylactic or therapeutic immunization against hiv |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
FR2805265B1 (en) | 2000-02-18 | 2002-04-12 | Aventis Pasteur | IMMUNOSTIMULATING OLIGONUCLEOTIDES |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
EP1259264A4 (en) | 2000-02-23 | 2005-08-31 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
AU2001239873A1 (en) | 2000-02-24 | 2001-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant treatment by in vivo activation of dendritic cells |
US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20020107212A1 (en) | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US6851845B2 (en) * | 2000-03-10 | 2005-02-08 | The Maitland Company, Inc. | Method and apparatus for processing waste material |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
AU2001249609A1 (en) | 2000-03-28 | 2001-10-08 | Department Of Veterans Affairs | Methods for increasing a cytotoxic T lymphocyte response in vivo |
US8246945B2 (en) * | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
EP1278550A4 (en) | 2000-04-07 | 2004-05-12 | Univ California | Synergistic improvements to polynucleotide vaccines |
US7524826B2 (en) | 2000-04-14 | 2009-04-28 | Mcmaster University And Hamilton Health Sciences Corporation | Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque |
US6321873B1 (en) * | 2000-04-21 | 2001-11-27 | Tra-Lor-Mate, Inc. | Ladder mounting system |
CA2407942A1 (en) | 2000-05-01 | 2001-11-08 | Hybridon, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
US6893821B2 (en) * | 2000-05-05 | 2005-05-17 | The Regents Of The University Of California | Agents that modulate DNA-PK activity and methods of use thereof |
AU2001259706A1 (en) | 2000-05-09 | 2001-11-20 | Reliable Biopharmaceutical, Inc. | Polymeric compounds useful as prodrugs |
DK1280521T3 (en) * | 2000-05-12 | 2005-08-08 | Pharmacia & Upjohn Co Llc | Vaccine composition, method of preparation thereof and method of vaccination of vertebrates |
US6339630B1 (en) * | 2000-05-18 | 2002-01-15 | The United States Of America As Represented By The United States Department Of Energy | Sealed drive screw operator |
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
EP1292331A2 (en) * | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
WO2001097843A2 (en) * | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
US20020165178A1 (en) * | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
JP5511117B2 (en) | 2000-07-27 | 2014-06-04 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | Vaccine for broad protection against diseases caused by Neisseria meningitidis |
AU8640501A (en) | 2000-07-31 | 2002-02-13 | Univ Yale | Innate immune system-directed vaccines |
US20020198165A1 (en) * | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
JP2005512499A (en) * | 2000-09-01 | 2005-05-12 | エピゲノミクス アーゲー | Diagnosing the onset of an ongoing or specific disease |
ES2299520T3 (en) | 2000-09-01 | 2008-06-01 | Epigenomics Ag | PROCEDURE FOR THE DETERMINATION OF THE DEGREE OF METHYLATION OF CERTAIN CITOSINES IN GENOMIC DNA IN THE SEQUENTIAL CONTEXT 5'-CPG-3 '. |
US20020091097A1 (en) * | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
WO2002022809A2 (en) * | 2000-09-15 | 2002-03-21 | Coley Pharmaceutical Gmbh | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
US6787524B2 (en) * | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
WO2002026757A2 (en) | 2000-09-26 | 2002-04-04 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
SE0003538D0 (en) * | 2000-09-29 | 2000-09-29 | Isconova Ab | New immunogenic complex |
US7537772B1 (en) * | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
FR2814958B1 (en) | 2000-10-06 | 2003-03-07 | Aventis Pasteur | VACCINE COMPOSITION |
PT1889630E (en) * | 2000-10-18 | 2012-02-29 | Glaxosmithkline Biolog Sa | Vaccines comprising mage antigen linked to protein d fragment |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
WO2002036767A2 (en) | 2000-11-02 | 2002-05-10 | Inex Pharmaceuticals Corporation | Therapeutic oligonucleotides of reduced toxicity |
EP1985702A3 (en) * | 2000-12-08 | 2010-08-18 | Coley Pharmaceutical GmbH | CPG-like nucleic acids and methods of use thereof |
US20020110840A1 (en) * | 2000-12-08 | 2002-08-15 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
AU2002248185A1 (en) * | 2000-12-14 | 2002-07-16 | Coley Pharmaceutical Group, Inc. | Inhibition of angiogenesis by nucleic acids |
EP1364010B1 (en) * | 2000-12-27 | 2010-06-16 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
US7337306B2 (en) * | 2000-12-29 | 2008-02-26 | Stmicroelectronics, Inc. | Executing conditional branch instructions in a data processor having a clustered architecture |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
US7713942B2 (en) | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
US7176296B2 (en) | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US20030129605A1 (en) | 2001-05-04 | 2003-07-10 | Dong Yu | Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages |
EP2545937A1 (en) * | 2001-06-05 | 2013-01-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
JP2005509591A (en) | 2001-06-15 | 2005-04-14 | リバファーム・インコーポレイテッド | Nucleoside vaccine adjuvant |
US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
EP2423335B1 (en) * | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
US20040132677A1 (en) | 2001-06-21 | 2004-07-08 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same-IV |
WO2003000232A2 (en) | 2001-06-25 | 2003-01-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides |
US20030003970A1 (en) | 2001-06-28 | 2003-01-02 | Alan Johnson | Portable communications device |
JP4370161B2 (en) | 2001-06-29 | 2009-11-25 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | HCVE1E2 vaccine composition |
US6982033B2 (en) * | 2001-07-13 | 2006-01-03 | Donald Hubbard H | Aerobic treatment plant with filter pipe |
WO2003040308A2 (en) | 2001-07-27 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
AU2002318944A1 (en) * | 2001-08-01 | 2003-02-17 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
US20030133988A1 (en) * | 2001-08-07 | 2003-07-17 | Fearon Karen L. | Immunomodulatory compositions, formulations, and methods for use thereof |
JP2005510462A (en) | 2001-08-10 | 2005-04-21 | ダイナバックス テクノロジーズ コーポレイション | Production of immunomodulating oligonucleotides and methods of use thereof |
AU2002361468A1 (en) * | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
SG177000A1 (en) * | 2001-08-17 | 2012-01-30 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
JP2005501550A (en) | 2001-08-30 | 2005-01-20 | スリーエム イノベイティブ プロパティズ カンパニー | Maturation of plasmacytoid dendritic cells using immune response modifier molecules |
US7514415B2 (en) * | 2002-08-01 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides |
US7514414B2 (en) * | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
ES2338305T3 (en) | 2001-09-28 | 2010-05-06 | Purdue Research Foundation | TREATMENT METHOD THAT USES BINDING-IMMUNOGEN CONJUGATES. |
BR0213097A (en) * | 2001-10-05 | 2005-02-01 | Coley Pharm Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
EP1434602B1 (en) | 2001-10-06 | 2014-12-17 | Merial Limited | CpG plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein D |
AU2002346960A1 (en) | 2001-10-06 | 2003-04-22 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
US20030139364A1 (en) * | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
WO2003039595A2 (en) | 2001-11-07 | 2003-05-15 | Inex Pharmaceuticals Corporation | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
DE60230340D1 (en) | 2001-11-16 | 2009-01-22 | 3M Innovative Properties Co | N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use |
TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
AU2002258011B2 (en) * | 2001-12-04 | 2009-01-08 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Chimeric molecule for the treatment of TH2-like cytokine mediated disorders |
DE10161755B4 (en) * | 2001-12-15 | 2005-12-15 | Infineon Technologies Ag | Contact pin for testing microelectronic components with spherical contacts |
US8466116B2 (en) * | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
EP1467755A1 (en) | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
US7741297B2 (en) | 2002-02-04 | 2010-06-22 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
US20030232443A1 (en) | 2002-06-18 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of centromere protein B expression |
EP3006043B1 (en) * | 2002-04-04 | 2019-05-29 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
CA2480176A1 (en) * | 2002-04-11 | 2003-10-23 | Zymogenetics, Inc. | Use of interleukin-24 to treat ovarian cancer |
KR20050009697A (en) * | 2002-04-22 | 2005-01-25 | 바이오니취 라이프 사이언시즈 인코포레이티드 | Oligonucleotide compositions and their use for the modulation of immune responses |
US6948271B2 (en) * | 2002-05-06 | 2005-09-27 | Innovative Supply, Inc. | Identification and tracking system for deceased bodies |
CN100505975C (en) * | 2002-05-08 | 2009-06-24 | Btu国际公司 | Plasma-assisted coating |
US20040009944A1 (en) | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
JP2005532315A (en) | 2002-05-10 | 2005-10-27 | イネックス ファーマシューティカルズ コーポレイション | Methylated immunostimulatory oligonucleotides and methods of use thereof |
EP1505942B1 (en) | 2002-05-10 | 2008-08-13 | Tekmira Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
WO2003100040A1 (en) | 2002-05-28 | 2003-12-04 | Merck Patent Gmbh | A method for generating antigen-presenting cells |
CA2388049A1 (en) * | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US20040009949A1 (en) * | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AU2003267986A1 (en) | 2002-07-03 | 2004-01-23 | Depuy Mitek, Inc. | Vaccines to induce mucosal immunity |
WO2004007743A2 (en) | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
CN1468957A (en) | 2002-07-19 | 2004-01-21 | 中国人民解放军第二军医大学 | Plasmid used as human therapeutic vaccine adjuvant |
US20050209183A1 (en) | 2002-07-25 | 2005-09-22 | Phenion Gmbh & Co. Kg | Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs |
EP1393745A1 (en) | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
NZ538628A (en) | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
AR040996A1 (en) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
US6928476B2 (en) * | 2002-08-23 | 2005-08-09 | Mirra, Inc. | Peer to peer remote data storage and collaboration |
US6744084B2 (en) * | 2002-08-29 | 2004-06-01 | Micro Technology, Inc. | Two-transistor pixel with buried reset channel and method of formation |
AU2003278816A1 (en) * | 2002-09-13 | 2004-04-30 | Idenix (Cayman) Limited | ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
US6994870B2 (en) * | 2002-09-18 | 2006-02-07 | Jaw-Ji Tsai | Local nasal immunotherapy with allergen strip for allergic rhinitis |
WO2004026888A2 (en) | 2002-09-19 | 2004-04-01 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
US6988995B2 (en) * | 2002-09-30 | 2006-01-24 | Carl Zeiss Meditec, Inc. | Method and system for detecting the effects of Alzheimer's disease in the human retina |
US8043622B2 (en) * | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
ZA200503511B (en) * | 2002-10-29 | 2006-10-25 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
WO2004041183A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of California | Methods of treating pulmonary fibrotic disorders |
US7758876B2 (en) * | 2002-11-01 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
US7956043B2 (en) * | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
KR100525321B1 (en) | 2002-12-13 | 2005-11-02 | 안웅식 | Pharmaceutical composition for prophylaxis and treatment of papillomavirus-derived diseases comprising papillomavirus antigen protein and CpG-oligodeoxynucleotide |
EP1575977B1 (en) * | 2002-12-23 | 2009-09-09 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US7625872B2 (en) | 2002-12-23 | 2009-12-01 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
WO2004064782A2 (en) | 2003-01-16 | 2004-08-05 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US7189781B2 (en) * | 2003-03-13 | 2007-03-13 | H.B. Fuller Licensing & Finance Inc. | Moisture curable, radiation curable sealant composition |
CN100355453C (en) | 2003-03-24 | 2007-12-19 | 英特塞尔股份公司 | Improved vaccines |
ZA200507562B (en) | 2003-03-26 | 2006-11-29 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
AU2004226605A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
WO2005016235A2 (en) * | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
WO2004094671A2 (en) | 2003-04-22 | 2004-11-04 | Coley Pharmaceutical Gmbh | Methods and products for identification and assessment of tlr ligands |
JP3887346B2 (en) * | 2003-04-28 | 2007-02-28 | 株式会社東芝 | Video signal processing apparatus, video signal processing method, and video display apparatus |
MXPA05012421A (en) | 2003-05-16 | 2006-02-22 | Hybridon Inc | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents. |
EP1484336A1 (en) * | 2003-06-02 | 2004-12-08 | Pevion Biotech Ltd. | Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines |
KR101137572B1 (en) | 2003-06-11 | 2012-05-30 | 이데라 파마슈티칼즈, 인코포레이티드 | Stabilized immunomodulatory oligonucleotides |
JPWO2004110489A1 (en) * | 2003-06-13 | 2006-07-20 | 第一アスビオファーマ株式会社 | Pharmaceutical composition for prevention or treatment of Th1-type immune disease |
DE602004028468D1 (en) * | 2003-06-17 | 2010-09-16 | Mannkind Corp | ATTACHMENT OF IMMUNE RESPONSES TO MHC CLASS I RESTRICTED EPITOPES, FOR PROPHYLACTIC OR THERAPEUTIC PURPOSES |
BRPI0411514A (en) | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | small molecule toll-like receptor antagonists |
US20040265833A1 (en) | 2003-06-23 | 2004-12-30 | Cathy Lofton-Day | Methods and nucleic acids for the analysis of colorectal cell proliferative disorders |
AU2004255470B2 (en) | 2003-07-10 | 2010-08-19 | Cytos Biotechnology Ag | Packaged virus-like particles |
DE602004030343D1 (en) | 2003-07-11 | 2011-01-13 | Intercell Ag | HCV VACCINE |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
EP1648913A4 (en) | 2003-07-15 | 2008-09-10 | Idera Pharmaceuticals Inc | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
US20060182793A1 (en) * | 2003-07-22 | 2006-08-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
US20050196411A1 (en) | 2003-08-28 | 2005-09-08 | Moss Ronald B. | Immunogenic HIV compositions and related methods |
NZ545536A (en) * | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
US20070110714A1 (en) | 2003-09-08 | 2007-05-17 | Norio Hayashi | Medicinal composition for treatment of chronic hepatitis c |
GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
WO2005027920A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency |
AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
EP1675614A2 (en) | 2003-10-11 | 2006-07-05 | Inex Pharmaceuticals Corp. | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
US20050087538A1 (en) * | 2003-10-23 | 2005-04-28 | Wolfe Darrell R. | Iceless multiple can cooler |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
CN101454451A (en) | 2003-10-30 | 2009-06-10 | 科勒制药有限公司 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
JP4088246B2 (en) * | 2003-12-05 | 2008-05-21 | 富士通株式会社 | Ring network master setting method and apparatus |
KR101138131B1 (en) | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
US20070172315A1 (en) * | 2003-12-18 | 2007-07-26 | Barrett Robert K | Method and Apparatus for Creating Soil or Rock Subsurface Support |
EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
KR100558851B1 (en) | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | Modified CpG oligodeoxynucleotide with improved immunoregulatory function |
US20080146488A1 (en) * | 2004-02-06 | 2008-06-19 | Mayo Foundation For Medical Education And Research | Complexed Polypeptide and Adjuvant for Improved Vaccines |
US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
EP1720568A2 (en) | 2004-02-19 | 2006-11-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
DK1716234T3 (en) | 2004-02-20 | 2014-01-20 | Mologen Ag | Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic immune stimulation in humans and higher animals |
CA2557443A1 (en) | 2004-03-12 | 2005-09-29 | Hybridon, Inc. | Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide |
AU2005243250A1 (en) * | 2004-04-02 | 2005-11-24 | Coley Pharmaceutical Gmbh | Immunostimulatory nucleic acids for inducing IL-10 responses |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
WO2005115449A1 (en) * | 2004-05-28 | 2005-12-08 | Alk-Abelló A/S | Method of treating allergy and infection by eliciting an iga antibody response |
US8399025B2 (en) * | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
CA2567789A1 (en) | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
US7756043B1 (en) * | 2004-06-09 | 2010-07-13 | Sprint Communications Company L.P. | Method for identifying high traffic origin-destination node pairs in a packet based network |
AU2005257938B2 (en) | 2004-06-15 | 2010-11-11 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
US7427405B2 (en) | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
EP1766610A1 (en) * | 2004-06-25 | 2007-03-28 | TC Electronic A/S | Method of evaluating perception intensity of an audio signal and a method of controlling an input audio signal on the basis of the evaluation |
CA2571899A1 (en) * | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
CA2574090A1 (en) * | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
WO2006015560A1 (en) | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunomodulating agent used in conjunction with chemotherapy |
US20060058261A1 (en) * | 2004-09-15 | 2006-03-16 | Andre Aube | Chitin derivatives for hyperlipidemia |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
KR100721928B1 (en) * | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | Pharmaceutical composition for treating or preventing dermatitis comprising CpG oligodeoxynucleotide |
WO2006053090A2 (en) | 2004-11-08 | 2006-05-18 | Idera Pharmaceuticals | Synergistic inhibition of vegf and modulation of the immune response |
CA2594382A1 (en) | 2005-01-07 | 2006-07-13 | Alk-Abello A/S | Method of preventive treatment of allergy by oromucosal administration of an allergy vaccine |
JP2008531018A (en) * | 2005-02-24 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Immunostimulatory oligonucleotide |
JP2008535859A (en) | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Methods for treating asthma exacerbated by infection |
WO2006116458A2 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
US7325152B2 (en) * | 2005-06-30 | 2008-01-29 | Infineon Technologies Ag | Synchronous signal generator |
US20090117132A1 (en) * | 2005-07-07 | 2009-05-07 | Pfizer, Inc. | Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment |
JP5481068B2 (en) * | 2005-08-31 | 2014-04-23 | アメリカ合衆国 | Methods for altering the immune response elicited by CpG oligodeoxynucleotides |
WO2007088423A2 (en) | 2005-09-16 | 2007-08-09 | Coley Pharmaceutical Gmbh | Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone |
US20090306177A1 (en) | 2005-09-16 | 2009-12-10 | Coley Pharmaceutical Gmbh | Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (Sirna) by Nucleotide Modification |
EA200800943A1 (en) | 2005-09-27 | 2008-12-30 | Коли Фармасьютикал Гмбх | MODULATION OF TLR-MEDIATED IMMUNE RESPONSES WITH THE USE OF OLIGONUCLEOTIDE ADAPTERS |
EA200801045A1 (en) * | 2005-10-12 | 2008-10-30 | Кэнсер Рисерч Текнолоджи Лтд. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS |
US20070093439A1 (en) | 2005-10-25 | 2007-04-26 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
EP1940472A1 (en) * | 2005-10-28 | 2008-07-09 | Index Pharmaceuticals AB | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
US20070243209A1 (en) * | 2005-10-28 | 2007-10-18 | Health Research, Inc. | Compositions and methods for prevention and treatment of fungal diseases |
PT1951299E (en) | 2005-11-04 | 2012-02-28 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
JP2009514839A (en) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Adjuvant influenza vaccine containing cytokine inducer |
US7776834B2 (en) | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
CA2628306C (en) | 2005-11-07 | 2014-06-17 | Sudhir Agrawal | Immunostimulatory oligonucleotide-based compounds with glycerol-linked dinucleotides and modified guanosines at cpg and uses thereof |
MX2008006004A (en) | 2005-11-07 | 2008-10-01 | Idera Pharmaceuticals Inc | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides. |
US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
KR20080072934A (en) * | 2005-11-25 | 2008-08-07 | 콜리 파마슈티칼 게엠베하 | Immunostimulatory oligoribonucleotides |
MX2008008279A (en) | 2005-12-20 | 2009-03-04 | Idera Pharmaceuticals Inc | Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments. |
EP1991678B2 (en) * | 2006-02-15 | 2020-07-15 | Rechtsanwalt Thomas Beck | Compositions and methods for oligonucleotide formulations |
DE102006007433A1 (en) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Immunostimulant adjuvant useful in vaccines against cancer or infectious diseases comprises a lipid-modified nucleic acid |
US20090081156A1 (en) * | 2006-08-03 | 2009-03-26 | William Soo Hoo | Bioactive molecular matrix and methods of use in the treatment of disease |
US20080124366A1 (en) * | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
AU2007284036A1 (en) * | 2006-08-16 | 2008-02-21 | Protiva Biotherapeutics, Inc. | Nucleic acid modulation of Toll-like receptor-mediated immune stimulation |
US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
SI2484375T1 (en) * | 2006-09-26 | 2018-08-31 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
CA2664156A1 (en) | 2006-09-27 | 2008-04-03 | Coley Pharmaceutical Group, Inc. | Compositions of tlr ligands and antivirals |
MX2009003398A (en) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
BRPI0718182A2 (en) | 2006-10-26 | 2014-02-25 | Coley Pharm Gmbh | OLIGORRIBONUCLEOTIDS AND THEIR USES. |
US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
MX2009005849A (en) * | 2006-12-04 | 2009-08-12 | Univ Illinois | Compositions and methods to treat cancer with cupredoxins and cpg rich dna. |
US8057804B2 (en) * | 2006-12-28 | 2011-11-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
CA2674051C (en) * | 2006-12-28 | 2017-10-31 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
US9452209B2 (en) * | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
CA2687441A1 (en) | 2007-05-17 | 2008-11-27 | Coley Pharmaceutical Group, Inc. | Class a oligonucleotides with immunostimulatory potency |
EP2190440A1 (en) * | 2007-08-13 | 2010-06-02 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
EP2187961A2 (en) * | 2007-08-21 | 2010-05-26 | Dynavax Technologies Corporation | Composition and methods of making and using influenza proteins |
WO2009027105A2 (en) * | 2007-08-31 | 2009-03-05 | Neurimmune Therapeutics Ag | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
US7892567B2 (en) * | 2007-10-01 | 2011-02-22 | Board Of Regents, The University Of Texas System | Methods and compositions for immunization against chlamydial infection and disease |
CN101820908A (en) | 2007-10-09 | 2010-09-01 | 科利制药公司 | The immune stimulatory oligonucleotide analogs that comprises modified sugar moieties |
AR069704A1 (en) * | 2007-12-18 | 2010-02-10 | Alcon Res Ltd | SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME |
US7720322B2 (en) * | 2008-06-30 | 2010-05-18 | Intuitive Surgical, Inc. | Fiber optic shape sensor |
TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
US20100166782A1 (en) * | 2008-07-25 | 2010-07-01 | Martha Karen Newell | Clip inhibitors and methods of modulating immune function |
US8053422B2 (en) * | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
-
1996
- 1996-10-30 US US08/738,652 patent/US6207646B1/en not_active Expired - Lifetime
-
1997
- 1997-10-30 ES ES10186177.1T patent/ES2624859T3/en not_active Expired - Lifetime
- 1997-10-30 AU AU52424/98A patent/AU5242498A/en not_active Abandoned
- 1997-10-30 CA CA2270345A patent/CA2270345C/en not_active Expired - Lifetime
- 1997-10-30 KR KR1019997003873A patent/KR100689942B1/en not_active IP Right Cessation
- 1997-10-30 EP EP06115801A patent/EP1746159A3/en not_active Withdrawn
- 1997-10-30 NZ NZ335397A patent/NZ335397A/en not_active IP Right Cessation
- 1997-10-30 EP EP10186177.1A patent/EP2360252B8/en not_active Expired - Lifetime
- 1997-10-30 CN CNA2007101300520A patent/CN101265285A/en active Pending
- 1997-10-30 AT AT97947311T patent/ATE332966T1/en active
- 1997-10-30 EP EP97947311A patent/EP0948510B1/en not_active Revoked
- 1997-10-30 DE DE69736331T patent/DE69736331T2/en not_active Revoked
- 1997-10-30 EP EP10186108A patent/EP2322615A1/en not_active Withdrawn
- 1997-10-30 ES ES97947311T patent/ES2268736T3/en not_active Expired - Lifetime
- 1997-10-30 CN CNB971993521A patent/CN100338086C/en not_active Expired - Lifetime
- 1997-10-30 DK DK97947311T patent/DK0948510T3/en active
- 1997-10-30 WO PCT/US1997/019791 patent/WO1998018810A1/en active IP Right Grant
- 1997-10-30 PT PT97947311T patent/PT948510E/en unknown
- 1997-10-30 JP JP52078498A patent/JP2001503267A/en active Pending
- 1997-10-30 EP EP06115792A patent/EP1714969A3/en not_active Withdrawn
-
2001
- 2001-03-27 US US09/818,918 patent/US20030050261A1/en not_active Abandoned
- 2001-12-14 AU AU97249/01A patent/AU775185B2/en not_active Expired
-
2003
- 2003-03-03 JP JP2003056446A patent/JP2003286174A/en not_active Withdrawn
- 2003-05-09 US US10/435,656 patent/US20050277604A1/en not_active Abandoned
- 2003-07-03 US US10/613,916 patent/US20050070491A1/en not_active Abandoned
- 2003-09-10 JP JP2003319045A patent/JP2004041224A/en not_active Withdrawn
- 2003-10-03 US US10/679,710 patent/US20040147468A1/en not_active Abandoned
- 2003-12-22 US US10/743,625 patent/US20040132685A1/en not_active Abandoned
-
2004
- 2004-01-30 US US10/769,282 patent/US7674777B2/en not_active Expired - Fee Related
- 2004-04-02 US US10/817,165 patent/US20040198688A1/en not_active Abandoned
- 2004-04-23 US US10/831,647 patent/US7402572B2/en not_active Expired - Fee Related
- 2004-05-17 US US10/847,642 patent/US20050004061A1/en not_active Abandoned
- 2004-06-24 US US10/877,407 patent/US20040229835A1/en not_active Abandoned
- 2004-07-02 US US10/884,852 patent/US20050059625A1/en not_active Abandoned
- 2004-07-09 US US10/888,785 patent/US7517861B2/en not_active Expired - Fee Related
- 2004-07-09 US US10/888,449 patent/US20050049215A1/en not_active Abandoned
- 2004-07-16 US US10/894,862 patent/US8058249B2/en not_active Expired - Fee Related
- 2004-07-16 US US10/894,657 patent/US20050054602A1/en not_active Abandoned
- 2004-08-26 US US10/928,762 patent/US20050123523A1/en not_active Abandoned
- 2004-10-01 US US10/956,494 patent/US7879810B2/en not_active Expired - Fee Related
- 2004-10-01 US US10/956,745 patent/US20050239732A1/en not_active Abandoned
- 2004-10-13 AU AU2004218696A patent/AU2004218696B2/en not_active Expired
- 2004-10-22 US US10/972,301 patent/US20050215500A1/en not_active Abandoned
- 2004-11-12 US US10/987,146 patent/US20050148537A1/en not_active Abandoned
-
2005
- 2005-01-07 US US11/031,460 patent/US8158592B2/en not_active Expired - Fee Related
- 2005-01-14 US US11/036,527 patent/US7723022B2/en not_active Expired - Fee Related
- 2005-02-25 US US11/067,587 patent/US8129351B2/en not_active Expired - Fee Related
- 2005-05-23 US US11/134,918 patent/US20050267064A1/en not_active Abandoned
- 2005-12-07 US US11/296,572 patent/US20060089326A1/en not_active Abandoned
-
2006
- 2006-08-11 US US11/503,483 patent/US7723500B2/en not_active Expired - Fee Related
- 2006-09-22 US US11/526,197 patent/US20070078104A1/en not_active Abandoned
- 2006-11-10 US US11/598,207 patent/US8258106B2/en not_active Expired - Fee Related
-
2007
- 2007-06-05 US US11/810,353 patent/US20080026011A1/en not_active Abandoned
-
2008
- 2008-07-25 JP JP2008192729A patent/JP5082063B2/en not_active Expired - Lifetime
- 2008-10-09 US US12/248,493 patent/US20090202575A1/en not_active Abandoned
-
2009
- 2009-03-25 US US12/383,824 patent/US7888327B2/en not_active Expired - Fee Related
-
2010
- 2010-03-10 JP JP2010053784A patent/JP2010150280A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002555A1 (en) * | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
Non-Patent Citations (5)
Title |
---|
CHEMICAL ABSTRACTS, 29 April 1994, Vol. 120, No. 15, Abstract No. 182630, FOX R.I., "Mechanism of Action of Hydroxychloroquine as an Antirheumatic Drug". * |
EUR. J. BIOCHEM., 1991, Vol. 200, SCHNELL N. et al., "Identification and Characterization of a Saccharomyces Cerevisiae Gene (PAR1) Conferring Resistance to Iron Chelators", pages 487-493. * |
J. BIOL. CHEM., October 1993, Vol. 268, No. 28, MOTTRAM J.C. et al., "A Novel CDC2-Related Protein Kinase from Leishmania Mexicana, LmmCRK1, is Post-Translationally Regulated During the Life Cycle", pages 21044-21052. * |
METHODS IN ENZYMOLOGY, 1987, Vol. 152, WALLACE R.B. et al., "Oligonucleotide Probes for the Screening of Recombinant DNA Libraries", pages 432-442. * |
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, April 1996, Vol. 77, BLAXTER M.L. et al., "Genes Expressed in Brugia Malayi Infective Third Stage Larvae", pages 77-93. * |
Cited By (390)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6083505A (en) * | 1992-04-16 | 2000-07-04 | 3M Innovative Properties Company | 1H-imidazo[4,5-C]quinolin-4-amines as vaccine adjuvants |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US8258106B2 (en) * | 1994-07-15 | 2012-09-04 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7723500B2 (en) | 1994-07-15 | 2010-05-25 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7888327B2 (en) | 1994-07-15 | 2011-02-15 | University Of Iowa Research Foundation | Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
US7901907B2 (en) | 1996-01-04 | 2011-03-08 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Process for production of Helicobacter pylori bacterioferritin |
US6610661B1 (en) | 1996-10-11 | 2003-08-26 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
US7208478B2 (en) | 1996-10-11 | 2007-04-24 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
US6200592B1 (en) | 1996-10-25 | 2001-03-13 | 3M Innovative Properties Company | Immine response modifier compounds for treatment of TH2 mediated and related diseases |
US6696076B2 (en) | 1996-10-25 | 2004-02-24 | 3M Innovative Properties Company | Immune response modifier compounds for treatment of TH2 mediated and related diseases |
US6610319B2 (en) | 1996-10-25 | 2003-08-26 | 3M Innovative Properties Company | Immune response modifier compounds for treatment of TH2 mediated and related diseases |
US7001890B1 (en) | 1997-01-23 | 2006-02-21 | Coley Pharmaceutical Gmbh | Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |
EP1039935A4 (en) * | 1997-02-28 | 2005-04-27 | Univ Iowa Res Found | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
EP1039935A1 (en) * | 1997-02-28 | 2000-10-04 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
EP2172216A3 (en) * | 1997-03-10 | 2010-11-24 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EP1005368A4 (en) * | 1997-03-10 | 2004-09-29 | Ottawa Health Research Inst | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
EP1408110A3 (en) * | 1997-04-30 | 2007-10-31 | Idera Pharmaceuticals, Inc. | Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
US7700570B2 (en) | 1997-04-30 | 2010-04-20 | Idera Pharmaceuticals, Inc. | Oligonucleotide mediated specific cytokine induction and prophylaxis and treatment of viral infection in a mammal |
WO1998049288A1 (en) * | 1997-04-30 | 1998-11-05 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
US6821957B2 (en) | 1997-05-20 | 2004-11-23 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
EP1374894A3 (en) * | 1997-06-06 | 2004-09-22 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO1998055495A2 (en) * | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1374894A2 (en) * | 1997-06-06 | 2004-01-02 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
AU753172B2 (en) * | 1997-06-06 | 2002-10-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US8729039B2 (en) | 1997-06-06 | 2014-05-20 | The Regents Of The University Of California | Use of inhibitory oligonucleotides to treat autoimmune disease |
WO1998055495A3 (en) * | 1997-06-06 | 1999-05-27 | Dynavax Tech Corp | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6225292B1 (en) | 1997-06-06 | 2001-05-01 | The Regents Of The University Of California | Inhibitors of DNA immunostimulatory sequence activity |
WO1999011275A3 (en) * | 1997-09-05 | 1999-06-03 | Univ California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
EP1872786A1 (en) * | 1997-09-05 | 2008-01-02 | The Regents of the University of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
AU2003203948B2 (en) * | 1997-09-05 | 2005-12-22 | The Regents Of The University Of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
US6498148B1 (en) | 1997-09-05 | 2002-12-24 | The Regents Of The University Of California | Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype |
US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
WO1999056755A1 (en) * | 1998-05-06 | 1999-11-11 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
EP1674574A1 (en) * | 1998-05-14 | 2006-06-28 | Coley Pharmaceutical GmbH | Methods for Regulating Hematopoiesis using CpG-Oligonucleotides |
WO1999058118A3 (en) * | 1998-05-14 | 2000-01-13 | Cpg Immunopharmaceuticals Gmbh | METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
WO1999058118A2 (en) * | 1998-05-14 | 1999-11-18 | Cpg Immunopharmaceuticals Gmbh | METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
JP2002514397A (en) * | 1998-05-14 | 2002-05-21 | コーリー ファーマシューティカル ゲーエムベーハー | Methods for hematopoietic regulation using CpG oligonucleotides |
AU760795B2 (en) * | 1998-05-14 | 2003-05-22 | Coley Pharmaceutical Gmbh | Methods for regulating hematopoiesis using CpG-oligonucleotides |
US6962720B2 (en) | 1998-05-19 | 2005-11-08 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US8324177B2 (en) | 1998-05-19 | 2012-12-04 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US6689398B2 (en) | 1998-05-19 | 2004-02-10 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US6746696B2 (en) | 1998-05-19 | 2004-06-08 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US7105186B2 (en) | 1998-05-19 | 2006-09-12 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US7670632B2 (en) | 1998-05-19 | 2010-03-02 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US6444233B1 (en) | 1998-05-19 | 2002-09-03 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US7985435B2 (en) | 1998-05-19 | 2011-07-26 | Research Development Foundation | Triterpene compositions and methods for use thereof |
WO1999061056A3 (en) * | 1998-05-22 | 2000-04-06 | Loeb Health Research Inst At T | Methods and products for inducing mucosal immunity |
WO1999061056A2 (en) * | 1998-05-22 | 1999-12-02 | Loeb Health Research Institute At The Ottawa Hospital | Methods and products for inducing mucosal immunity |
AU761899B2 (en) * | 1998-05-22 | 2003-06-12 | Ottawa Health Research Institute | Methods and products for inducing mucosal immunity |
JP2002516294A (en) * | 1998-05-22 | 2002-06-04 | ローブ ヘルス リサーチ インスティチュート アット ザ オタワ ホスピタル | Methods and products for inducing mucosal immunity |
EP1733735A3 (en) * | 1998-05-22 | 2008-08-27 | Ottawa Health Research Institute | Methods and products for inducing mucosal immunity |
JP2009060909A (en) * | 1998-05-27 | 2009-03-26 | Cj Cheil Jedang Corp | Novel endonuclease of immunocyte, method for production thereof, and immunoadjuvant using the same |
WO2000006588A1 (en) * | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
US7049302B1 (en) | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
US7858589B2 (en) | 1998-08-10 | 2010-12-28 | Antigenics Inc. | Compositions of CpG and saponin adjuvants and uses thereof |
JP2002522510A (en) * | 1998-08-10 | 2002-07-23 | アクウィラ・バイオファーマシューティカルズ・インコーポレイテッド | Compositions of CPG and saponin adjuvant and methods thereof |
WO2000021556A1 (en) * | 1998-10-09 | 2000-04-20 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
AU770464B2 (en) * | 1998-12-22 | 2004-02-19 | Seer Pharmaceuticals, Llc | Treatment of skin lesions |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
US8173141B2 (en) | 1999-02-17 | 2012-05-08 | Csl Limited | Immunogenic complexes and methods relating thereto |
US8221761B1 (en) | 1999-02-26 | 2012-07-17 | Novartis Ag | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing CG motifs |
WO2000050075A2 (en) * | 1999-02-26 | 2000-08-31 | Chiron S.P.A. | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
WO2000050075A3 (en) * | 1999-02-26 | 2001-01-11 | Chiron Spa | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
JP2010174044A (en) * | 1999-02-26 | 2010-08-12 | Chiron Srl | Enhancement of bactericidal activity of neisseria antigen with oligonucleotide containing cg motif |
JP4812942B2 (en) * | 1999-02-26 | 2011-11-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Enhancement of Neisseria antigen bactericidal activity using oligonucleotides containing CG motif |
JP2002537353A (en) * | 1999-02-26 | 2002-11-05 | カイロン エセ.ピー.アー. | Enhancement of Neisseria antigen bactericidal activity using oligonucleotide containing CG motif |
EP2286792A1 (en) | 1999-02-26 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with an adsorbent surface, comprising a microdroplet emulsion |
GB2348132A (en) * | 1999-03-02 | 2000-09-27 | Nassief Nida Abdul Ghani | Uses for glycophosphopeptical |
GB2348132B (en) * | 1999-03-02 | 2004-08-04 | Nedaa Abdul-Ghani Nasif | Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils |
FR2790955A1 (en) * | 1999-03-19 | 2000-09-22 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
US7108844B2 (en) | 1999-03-19 | 2006-09-19 | Assistance Publique-Hopitaux De Paris | Use of stabilized oligonucleotides for preparing a medicament with antitumor activity |
US7700569B1 (en) | 1999-03-19 | 2010-04-20 | Assistance Publique-Hopitaux De Paris | Use of stabilised oligonucleotides for preparing a medicine with antitumor activity |
WO2000056342A2 (en) * | 1999-03-19 | 2000-09-28 | Assistance Publique-Hopitaux De Paris | Use of stabilised oligonucleotides for preparing a medicine with antitumour activity |
WO2000056342A3 (en) * | 1999-03-19 | 2001-07-26 | Assist Publ Hopitaux De Paris | Use of stabilised oligonucleotides for preparing a medicine with antitumour activity |
US8030285B2 (en) * | 1999-04-12 | 2011-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US8741869B2 (en) | 1999-04-12 | 2014-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2000061151A3 (en) * | 1999-04-12 | 2001-04-26 | Us Health | Oligodeoxynucleotide and its use to induce an immune response |
US8389495B2 (en) | 1999-04-12 | 2013-03-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Olioodeoxynucleotide and its use to induce an immune response |
WO2000062803A2 (en) * | 1999-04-15 | 2000-10-26 | Board Of Regents, The University Of Texas System | ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS |
US6562801B1 (en) | 1999-04-15 | 2003-05-13 | Board Of Regents, The University Of Texas System | PpGpp and pppGpp as immunomodulatory agents |
WO2000062803A3 (en) * | 1999-04-15 | 2001-01-18 | Univ Texas | ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS |
CZ303515B6 (en) * | 1999-04-19 | 2012-11-07 | Smithkline Beecham Biologicals S. A. | Adjuvant compositions |
US7399472B2 (en) | 1999-04-19 | 2008-07-15 | Smithkline Beecham Biologicals | Vaccines |
JP2007191491A (en) * | 1999-04-19 | 2007-08-02 | Glaxosmithkline Biologicals Sa | Vaccine |
US6544518B1 (en) | 1999-04-19 | 2003-04-08 | Smithkline Beecham Biologicals S.A. | Vaccines |
WO2000062800A2 (en) * | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
EP1541170A1 (en) * | 1999-04-19 | 2005-06-15 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
WO2000062800A3 (en) * | 1999-04-19 | 2001-01-11 | Smithkline Beecham Biolog | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
JP2011241222A (en) * | 1999-04-19 | 2011-12-01 | Glaxosmithkline Biologicals Sa | Vaccine |
JP2002542203A (en) * | 1999-04-19 | 2002-12-10 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | vaccine |
EP2322210A1 (en) * | 1999-04-19 | 2011-05-18 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
AU762857B2 (en) * | 1999-04-20 | 2003-07-10 | Smithkline Beecham Biologicals (Sa) | Vaccine |
WO2000062802A2 (en) * | 1999-04-20 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Vaccine comprising rsv antigen and cpg oligonucleotide |
WO2000062802A3 (en) * | 1999-04-20 | 2001-01-11 | Smithkline Beecham Biolog | Vaccine comprising rsv antigen and cpg oligonucleotide |
FR2795963A1 (en) * | 1999-07-08 | 2001-01-12 | Pasteur Merieux Serums Vacc | New polynucleotides are useful as vaccines for humans |
WO2001007055A1 (en) * | 1999-07-27 | 2001-02-01 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Covalently closed immunostimulating nucleic acid molecule |
DE19935756A1 (en) * | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Covalently closed nucleic acid molecule for immune stimulation |
US6849725B2 (en) | 1999-07-27 | 2005-02-01 | Mologen Forschungs Entwicklungs Und Vertriebs Gmbh | Covalently closed nucleic acid molecules for immunostimulation |
WO2001012804A3 (en) * | 1999-08-13 | 2001-09-07 | Hybridon Inc | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
WO2001012804A2 (en) * | 1999-08-13 | 2001-02-22 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
US8333980B2 (en) | 1999-08-19 | 2012-12-18 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
US7479285B1 (en) | 1999-08-19 | 2009-01-20 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
CN100368020C (en) * | 1999-08-27 | 2008-02-13 | 不列颠哥伦比亚大学 | Compositions for stimulating cytokine secretion and inducing an immune response |
WO2001015726A2 (en) * | 1999-08-27 | 2001-03-08 | Inex Pharmaceuticals Corp. | Compositions for stimulating cytokine secretion and inducing an immune response |
WO2001015726A3 (en) * | 1999-08-27 | 2001-07-26 | Inex Pharmaceuticals Corp | Compositions for stimulating cytokine secretion and inducing an immune response |
JP2003509341A (en) * | 1999-08-27 | 2003-03-11 | イネックス ファーマスーティカルズ コーポレイション | Composition for stimulating secretion of cytokine and inducing immune response |
JP2003510282A (en) * | 1999-09-25 | 2003-03-18 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Immunostimulatory nucleic acids |
WO2001022990A3 (en) * | 1999-09-27 | 2001-10-04 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
EP1688147A1 (en) * | 1999-09-27 | 2006-08-09 | Coley Pharmaceutical Group, Inc. | Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US7776344B2 (en) | 1999-09-27 | 2010-08-17 | University Of Iowa Research Foundation | Methods related to immunostimulatory nucleic acid-induced interferon |
US9067987B2 (en) | 1999-10-29 | 2015-06-30 | Glaxosmithkline Biologicals Sa | Neisserial antigenic peptides |
US8394390B2 (en) | 1999-10-29 | 2013-03-12 | Novartis Ag | Neisserial antigenic peptides |
US8734812B1 (en) | 1999-10-29 | 2014-05-27 | Novartis Ag | Neisserial antigenic peptides |
US7628990B2 (en) | 1999-11-15 | 2009-12-08 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
US7919477B2 (en) | 2000-01-14 | 2011-04-05 | The United States Of America As Represented By The Department Of Health And Human Services | Multiple CpG oligodeoxynucleotides and their use to induce an immune response |
US8232259B2 (en) | 2000-01-14 | 2012-07-31 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multiple CpG oligodeoxynucleotide and their use to induce an immune response |
WO2001051500A1 (en) * | 2000-01-14 | 2001-07-19 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
EP1259264A2 (en) * | 2000-02-23 | 2002-11-27 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US7485627B2 (en) | 2000-02-23 | 2009-02-03 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
EP1259264A4 (en) * | 2000-02-23 | 2005-08-31 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US8226957B2 (en) | 2000-03-10 | 2012-07-24 | Dynavax Technologies Corporation | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences |
US7250403B2 (en) | 2000-03-10 | 2007-07-31 | Dynavax Technologies Corporation | Biodegradable immunomodulatory formulations and methods for use thereof |
US8669237B2 (en) | 2000-03-10 | 2014-03-11 | Dynavax Technologies Corporation | Biodegradable immunomodulatory formulations and methods for use thereof |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US8124590B2 (en) | 2000-03-10 | 2012-02-28 | Dynavax Technologies Corporation | Biodegradable immunomodulatory formulations and methods for use thereof |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7727712B2 (en) | 2000-03-10 | 2010-06-01 | Dynavax Technologies Corporation | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
EP2067487A2 (en) | 2000-03-10 | 2009-06-10 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7183111B2 (en) | 2000-03-10 | 2007-02-27 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
WO2001076642A1 (en) * | 2000-04-07 | 2001-10-18 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
JP2003535907A (en) * | 2000-06-22 | 2003-12-02 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Method for promoting antibody-induced cell lysis and treating cancer |
WO2002002172A3 (en) * | 2000-06-30 | 2002-10-10 | Univ Jefferson | Dna palindrome - oligoguanylic acid compositions and uses thereof |
WO2002002172A1 (en) * | 2000-06-30 | 2002-01-10 | Univ Jefferson | Dna palindrome - oligoguanylic acid compositions and uses thereof |
US7820379B2 (en) | 2000-09-15 | 2010-10-26 | Coley Pharmaceutical Gmbh | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
US6943240B2 (en) | 2000-09-15 | 2005-09-13 | Coley Pharmaceuticals Gmbh | Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist |
EP2284181A1 (en) | 2000-10-27 | 2011-02-16 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A and B |
EP2284182A1 (en) | 2000-10-27 | 2011-02-16 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A and B |
EP2277896A1 (en) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
EP2284183A1 (en) | 2000-10-27 | 2011-02-16 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A and B |
EP2277895A1 (en) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
EP2277894A1 (en) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
EP2896629A1 (en) | 2000-10-27 | 2015-07-22 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus group A & B |
EP1985702A2 (en) | 2000-12-08 | 2008-10-29 | Coley Pharmaceuticals GmbH | CPG-like nucleic acids and methods of use thereof |
US8372413B2 (en) | 2000-12-27 | 2013-02-12 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
WO2002055090A1 (en) * | 2001-01-12 | 2002-07-18 | Amato Pharmaceutical Products,Ltd. | Preventives for microbial infections |
WO2002060476A3 (en) * | 2001-01-31 | 2003-01-23 | Mologen Forschungs Entwicklung | Tumor vaccine |
WO2002060476A2 (en) * | 2001-01-31 | 2002-08-08 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Tumor vaccine |
US7858588B2 (en) | 2001-05-21 | 2010-12-28 | Intercell Ag | Immunostimulatory oligodeoxynucleic molecules |
EP2277536A2 (en) | 2001-06-20 | 2011-01-26 | Novartis AG | Purification of bacterial capsular polysaccharides |
EP2263688A1 (en) | 2001-06-20 | 2010-12-22 | Novartis AG | Neisseria meningitidis combination vaccines |
EP2277539A2 (en) | 2001-06-20 | 2011-01-26 | Novartis AG | Neisseria meningitidis conjugate combination vaccine |
EP2277537A2 (en) | 2001-06-20 | 2011-01-26 | Novartis AG | Neisseria meningitidis conjugate combination vaccine |
US7255868B2 (en) | 2001-06-21 | 2007-08-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—I |
EP2423335A2 (en) | 2001-06-21 | 2012-02-29 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
US9028845B2 (en) | 2001-06-21 | 2015-05-12 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same-IV |
EP2266605A1 (en) | 2001-07-26 | 2010-12-29 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
EP2255827A1 (en) | 2001-07-26 | 2010-12-01 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
EP2168597A1 (en) | 2001-07-26 | 2010-03-31 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
WO2003014316A2 (en) | 2001-08-07 | 2003-02-20 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
US8586555B2 (en) | 2001-08-07 | 2013-11-19 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
US8834900B2 (en) | 2001-08-17 | 2014-09-16 | University Of Iowa Research Foundation | Combination motif immune stimulatory oligonucleotides with improved activity |
US7745395B2 (en) | 2001-08-24 | 2010-06-29 | University of Victoria Innovatiion and Development Corporation | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
US7282476B2 (en) | 2001-08-24 | 2007-10-16 | University Of Victoria Innovation And Development Corporation | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
US7838266B2 (en) | 2001-08-24 | 2010-11-23 | University Of Victoria Innovation And Development Corporation | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
EP2327719A1 (en) | 2001-09-06 | 2011-06-01 | Novartis Vaccines and Diagnostics S.r.l. | Hybrid and tandem expression of neisserial proteins |
EP2360176A2 (en) | 2001-09-06 | 2011-08-24 | Novartis Vaccines and Diagnostics S.r.l. | Hybrid and tandem expression of neisserial derived proteins |
EP2829549A2 (en) | 2001-09-06 | 2015-01-28 | Novartis Vaccines and Diagnostics S.r.l. | Hybrid and tandem expression of neisserial derived proteins |
US7709451B2 (en) | 2001-09-07 | 2010-05-04 | Trustees Of Boston University | Method and composition for treating immune complex associated disorders |
EP1435987A4 (en) * | 2001-09-07 | 2005-11-23 | Univ Boston | Method and composition for treating immune complex associated disorders |
EP1435987A1 (en) * | 2001-09-07 | 2004-07-14 | The Trustees of Boston University | Method and composition for treating immune complex associated disorders |
US9950055B2 (en) | 2001-09-14 | 2018-04-24 | Kuros Biosciences Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US8691209B2 (en) | 2001-09-14 | 2014-04-08 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US8580944B2 (en) | 2001-09-24 | 2013-11-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
US9163244B2 (en) | 2001-09-24 | 2015-10-20 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
US8227438B2 (en) | 2001-09-24 | 2012-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
US7514414B2 (en) | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
WO2003028656A2 (en) | 2001-10-03 | 2003-04-10 | Chiron Corporation | Adjuvant compositions |
WO2003030656A2 (en) | 2001-10-06 | 2003-04-17 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
WO2003066649A1 (en) * | 2002-02-04 | 2003-08-14 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
US7741297B2 (en) | 2002-02-04 | 2010-06-22 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
WO2003070909A2 (en) | 2002-02-20 | 2003-08-28 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
EP2572707A2 (en) | 2002-02-20 | 2013-03-27 | Novartis Vaccines and Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
US7507802B2 (en) * | 2002-05-22 | 2009-03-24 | Eyegene, Inc. | Immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides |
JP2005532067A (en) * | 2002-07-03 | 2005-10-27 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Nucleic acid composition for stimulating immune response |
US7528223B2 (en) | 2002-07-24 | 2009-05-05 | Intercell Ag | Antigens encoded by alternative reading frames from pathogenic viruses |
WO2004011650A2 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
US8557789B2 (en) | 2002-08-01 | 2013-10-15 | The United States of America as represented by the Secretary of the Development of Health and Human Services | Method of treating inflammatory arthropathies with supressors of CPG oligonucleotides |
US7951786B2 (en) | 2002-08-01 | 2011-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides |
US7514415B2 (en) | 2002-08-01 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides |
US8288359B2 (en) | 2002-08-01 | 2012-10-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides |
US8283328B2 (en) | 2002-08-19 | 2012-10-09 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
EP1538904A2 (en) * | 2002-08-19 | 2005-06-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
US8304396B2 (en) | 2002-08-19 | 2012-11-06 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
WO2004016805A2 (en) | 2002-08-19 | 2004-02-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
AU2003259916B2 (en) * | 2002-08-19 | 2010-01-21 | Coley Pharmaceutical Gmbh | Immunostimulatory nucleic acids |
EP2290078A3 (en) * | 2002-08-19 | 2013-02-13 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
EP1538904A4 (en) * | 2002-08-19 | 2008-03-05 | Coley Pharm Group Inc | Immunostimulatory nucleic acids |
EP2258388A1 (en) | 2002-08-30 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Improved bacterial outer membrane vesicles |
EP2258390A1 (en) | 2002-08-30 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Improved bacterial outer membrane vesicles |
EP2258389A1 (en) | 2002-08-30 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Improved bacterial outer membrane vesicles |
US20140056931A1 (en) * | 2002-09-05 | 2014-02-27 | University Of South Florida | Genetic adjuvants for immunotherapy |
EP2402026A2 (en) | 2002-09-13 | 2012-01-04 | Intercell AG | Method for isolating hepatitis C virus peptides |
US7378234B2 (en) | 2002-09-13 | 2008-05-27 | Intercell Ag | Method for isolating hepatitis C virus peptides |
WO2004031382A1 (en) * | 2002-10-02 | 2004-04-15 | Mochida Pharmaceutical Co., Ltd. | Novel method of constructing monoclonal antibody |
US9006203B2 (en) | 2002-10-08 | 2015-04-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of reducing inflammatory infiltration in subjects with inflammatory lung disease |
US8501188B2 (en) | 2002-10-08 | 2013-08-06 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
EP1572122A4 (en) * | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
EP1572122A2 (en) * | 2002-11-01 | 2005-09-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
US8481055B2 (en) | 2002-11-01 | 2013-07-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
EP2279746A2 (en) | 2002-11-15 | 2011-02-02 | Novartis Vaccines and Diagnostics S.r.l. | Surface proteins in neisseria meningitidis |
EP2258716A2 (en) | 2002-11-22 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Multiple variants of meningococcal protein NMB1870 |
EP2258717A2 (en) | 2002-11-22 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Variant form of meningococcal NadA |
EP2261239A2 (en) | 2002-11-22 | 2010-12-15 | Novartis Vaccines and Diagnostics S.r.l. | Multiple variants of meningococcal protein NMB1870 |
US8871732B2 (en) | 2002-12-23 | 2014-10-28 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US7745606B2 (en) | 2002-12-23 | 2010-06-29 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US9422564B2 (en) | 2002-12-23 | 2016-08-23 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US10196643B2 (en) | 2002-12-23 | 2019-02-05 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
EP1992635A1 (en) | 2002-12-23 | 2008-11-19 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US11312965B2 (en) | 2002-12-23 | 2022-04-26 | Trisalus Life Sciences, Inc. | Immunostimulatory sequence oligonucleotides and methods of using the same |
EP2263687A1 (en) | 2002-12-27 | 2010-12-22 | Novartis Vaccines&Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
US8071371B2 (en) | 2003-02-26 | 2011-12-06 | Humabs Llc | Monoclonal antibody production by EBV transformation of B cells |
US9290786B2 (en) | 2003-02-26 | 2016-03-22 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
US8784837B2 (en) | 2003-03-24 | 2014-07-22 | Valneva Austria Gmbh | Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule |
WO2004084938A1 (en) | 2003-03-24 | 2004-10-07 | Intercell Ag | Improved vaccines |
EP2345420A1 (en) | 2003-03-24 | 2011-07-20 | Intercell AG | Use of a TH1 immune response inducing adjuvant for enhancing immune responses |
US7704514B2 (en) | 2003-03-24 | 2010-04-27 | Intercell Ag | Vaccines |
US7517520B2 (en) | 2003-03-26 | 2009-04-14 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
US7871984B2 (en) * | 2003-04-23 | 2011-01-18 | Yukio Sato | Methylated CpG polynucleotide |
US7790189B2 (en) * | 2003-05-15 | 2010-09-07 | Mitsui Sugar Co., Ltd. | Immunostimulating agents |
EP2179729A1 (en) | 2003-06-02 | 2010-04-28 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
EP1631576A4 (en) * | 2003-06-11 | 2010-08-25 | Idera Pharmaceuticals Inc | Stabilized immunomodulatory oligonucleotides |
CN102604957B (en) * | 2003-06-11 | 2015-10-07 | 艾德拉药物股份有限公司 | Stable immunomodulatory oligonucleotide |
EP2371834A1 (en) * | 2003-06-11 | 2011-10-05 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
EP1631576A2 (en) * | 2003-06-11 | 2006-03-08 | Hybridon, Inc. | Stabilized immunomodulatory oligonucleotides |
WO2005039634A1 (en) * | 2003-10-13 | 2005-05-06 | Glaxosmithkline Biologicals Sa | Vaccine compositions comprising an interleukin 18 and saponin adjuvant system |
EP2545931A1 (en) | 2004-03-19 | 2013-01-16 | Herbs Spring, LLC | Herbal therapy for the treatment of food allergy |
WO2005111057A3 (en) * | 2004-04-02 | 2006-07-27 | Coley Pharm Group Inc | Immunostimulatory nucleic acids for inducing il-10 responses |
WO2005111057A2 (en) * | 2004-04-02 | 2005-11-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing il-10 responses |
US8895521B2 (en) | 2004-05-06 | 2014-11-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the treatment of uveitis |
EP2149583A1 (en) | 2004-09-24 | 2010-02-03 | Intercell AG | Modified VP1-capsid protein of parvovirus B19 |
US9809824B2 (en) | 2004-12-13 | 2017-11-07 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
EP2433647A2 (en) | 2005-01-27 | 2012-03-28 | Children's Hospital & Research Center at Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
WO2006086799A2 (en) | 2005-02-11 | 2006-08-17 | Novartis Vaccines And Diagnostics Inc. | Prion-specific peptide reagents |
US8101345B1 (en) | 2005-03-25 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Proinflammatory nucleic acids |
US8642577B2 (en) | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
US9950029B2 (en) | 2005-06-14 | 2018-04-24 | Sophiris Bio Inc. | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
US8916161B2 (en) | 2005-06-14 | 2014-12-23 | Sophiris Bio Inc. | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
US8574564B2 (en) | 2005-12-14 | 2013-11-05 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
WO2007119815A1 (en) | 2006-04-14 | 2007-10-25 | Kyowa Hakko Kirin Co., Ltd. | Toll-like receptor 9 agonists |
US8592566B2 (en) | 2006-05-31 | 2013-11-26 | Toray Industries, Inc. | Immunostimulatory oligonucleotides and use thereof in pharmaceuticals |
US9902972B2 (en) | 2006-06-12 | 2018-02-27 | Kuros Biosciences Ag | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
US9404126B2 (en) | 2006-06-12 | 2016-08-02 | Kuros Biosciences Ag | Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages |
US10358656B2 (en) | 2006-06-12 | 2019-07-23 | Kuros Biosciences Ag | Oligonucleotides packaged into virus-like particles of RNA bacteriophages |
US9549980B2 (en) | 2007-04-19 | 2017-01-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating necrotizing enterocolitis by administering nuclear oligomerization domain-2 agonists,TLR9 agonists and TLR4 antagonists |
EP3067048A1 (en) | 2007-12-07 | 2016-09-14 | Novartis Ag | Compositions for inducing immune responses |
US8993542B2 (en) | 2008-01-25 | 2015-03-31 | Chimerix Inc. | Methods of treating viral infections |
EP2631245A1 (en) | 2008-03-10 | 2013-08-28 | Children's Hospital & Research Center at Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
US8222225B2 (en) | 2008-05-21 | 2012-07-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating pneumoconiosis with oligodeoxynucleotides |
US10329318B2 (en) | 2008-12-02 | 2019-06-25 | Wave Life Sciences Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
US9695211B2 (en) | 2008-12-02 | 2017-07-04 | Wave Life Sciences Japan, Inc. | Method for the synthesis of phosphorus atom modified nucleic acids |
US8552165B2 (en) | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
US8475801B2 (en) | 2008-12-09 | 2013-07-02 | Pfizer Vaccines, LCC | IgE CH3 peptide vaccine |
WO2010067286A2 (en) | 2008-12-09 | 2010-06-17 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE |
US9453059B2 (en) | 2008-12-09 | 2016-09-27 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
EP2865389A1 (en) | 2008-12-09 | 2015-04-29 | Pfizer Vaccines LLC | IgE CH3 peptide vaccine |
EP2759306A1 (en) | 2008-12-09 | 2014-07-30 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
US8298547B2 (en) | 2008-12-09 | 2012-10-30 | Pfizer Vaccines, LLC | IgE CH3 peptide vaccine |
WO2010067262A1 (en) | 2008-12-09 | 2010-06-17 | Pfizer Inc. | Immunostimulatory oligonucleotides |
US9216229B2 (en) | 2008-12-09 | 2015-12-22 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
US11633503B2 (en) | 2009-01-08 | 2023-04-25 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
US9205143B2 (en) | 2009-04-30 | 2015-12-08 | Coley Pharmaceutical Group Inc. | Pneumococcal vaccine and uses thereof |
US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
US10307434B2 (en) | 2009-07-06 | 2019-06-04 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
WO2011007961A2 (en) | 2009-07-17 | 2011-01-20 | Industry Academic Cooperation Foundation, Hallym University | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes |
WO2011013034A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
WO2011027257A2 (en) | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
EP3358008A1 (en) | 2009-09-03 | 2018-08-08 | Pfizer Vaccines LLC | Pcsk9 vaccine |
EP2865752A1 (en) | 2009-09-03 | 2015-04-29 | Pfizer Vaccines LLC | PCSK9 vaccine |
WO2011077309A2 (en) | 2009-12-22 | 2011-06-30 | Pfizer Vaccines Llc | Vaccine compositions |
EP3257525A2 (en) | 2009-12-22 | 2017-12-20 | Celldex Therapeutics, Inc. | Vaccine compositions |
US9765100B2 (en) | 2010-02-12 | 2017-09-19 | Chimerix, Inc. | Nucleoside phosphonate salts |
US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
WO2011109422A2 (en) | 2010-03-02 | 2011-09-09 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
WO2011109422A3 (en) * | 2010-03-02 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
US8685416B2 (en) | 2010-03-02 | 2014-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
EP3327028A1 (en) | 2010-03-30 | 2018-05-30 | Children's Hospital & Research Center at Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
EP4036104A1 (en) | 2010-03-30 | 2022-08-03 | Children's Hospital & Research Center at Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
US9956239B2 (en) | 2010-04-26 | 2018-05-01 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
US9694024B2 (en) | 2010-04-26 | 2017-07-04 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
WO2011148356A1 (en) | 2010-05-28 | 2011-12-01 | Coley Pharmaceutical Group, Inc. | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules |
US8722053B2 (en) | 2010-06-07 | 2014-05-13 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
EP2942061A2 (en) | 2010-06-07 | 2015-11-11 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
US9249233B2 (en) | 2010-06-07 | 2016-02-02 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
US10300083B2 (en) | 2010-09-24 | 2019-05-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
US10933077B2 (en) | 2010-09-24 | 2021-03-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
US11413299B2 (en) | 2010-09-24 | 2022-08-16 | The Johns Hopkins University | Compositions and methods for treatment of inflammatory disorders |
US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
US10172848B2 (en) | 2010-12-22 | 2019-01-08 | University of Pittsburgh—Of the Commonwealth Systems of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
KR20160113332A (en) | 2010-12-23 | 2016-09-28 | 몰로젠 아게 | Non-coding immunomodulatory dna construct |
US9364531B2 (en) | 2010-12-30 | 2016-06-14 | Intervet Inc. | Immunostimulatory oligodeoxynucleotides |
RU2615457C2 (en) * | 2010-12-30 | 2017-04-04 | Интервет Интернэшнл Б.В. | Immunostimulating oligodeoxynucleotides |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
US10280192B2 (en) | 2011-07-19 | 2019-05-07 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
US11071776B2 (en) | 2012-04-23 | 2021-07-27 | N-Fold Llc | Nanoparticles for treatment of allergy |
WO2013162828A1 (en) | 2012-04-27 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing |
EP3563865A2 (en) | 2012-05-04 | 2019-11-06 | Pfizer Inc | Prostate-associated antigens and vaccine-based immunotherapy regimens |
WO2013164754A2 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
US9617547B2 (en) | 2012-07-13 | 2017-04-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
US10167309B2 (en) | 2012-07-13 | 2019-01-01 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
US9982257B2 (en) | 2012-07-13 | 2018-05-29 | Wave Life Sciences Ltd. | Chiral control |
RU2677639C2 (en) * | 2012-07-13 | 2019-01-18 | Шин Ниппон Биомедикал Лэбораториз, Лтд. | Chiral nucleic acid adjuvant |
AU2013287630B2 (en) * | 2012-07-13 | 2017-05-25 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
US10590413B2 (en) | 2012-07-13 | 2020-03-17 | Wave Life Sciences Ltd. | Chiral control |
US9562066B2 (en) * | 2012-09-25 | 2017-02-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
US20140086982A1 (en) * | 2012-09-25 | 2014-03-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
DE102013004595A1 (en) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV vaccines |
US9539217B2 (en) | 2013-04-03 | 2017-01-10 | Allertein Therapeutics, Llc | Nanoparticle compositions |
US9999600B2 (en) | 2013-04-03 | 2018-06-19 | N-Fold Llc | Nanoparticle compositions |
WO2014173814A1 (en) | 2013-04-22 | 2014-10-30 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies against human csf-1r and tlr9 agonist |
EP3689375A1 (en) | 2013-05-15 | 2020-08-05 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
WO2014201245A1 (en) | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
US11512133B2 (en) | 2013-09-12 | 2022-11-29 | Hoffmann-La Roche Inc. | Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1 |
US11883535B2 (en) | 2013-12-03 | 2024-01-30 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
EP3095460A4 (en) * | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
US10160969B2 (en) | 2014-01-16 | 2018-12-25 | Wave Life Sciences Ltd. | Chiral design |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2015110941A2 (en) | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US11872274B2 (en) | 2014-01-21 | 2024-01-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US9492559B2 (en) | 2014-01-21 | 2016-11-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
EP3607966A1 (en) | 2014-01-21 | 2020-02-12 | Pfizer Inc | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
EP3616716A2 (en) | 2014-01-21 | 2020-03-04 | Pfizer Inc | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US10925938B2 (en) | 2014-02-11 | 2021-02-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Composition comprising PCSK9 peptide conjugated to a Qbeta carrier and methods of using the same |
US11696941B2 (en) | 2014-02-11 | 2023-07-11 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions comprising a PCSK9 peptide conjugated to a qbeta carrier and methods of using the same |
US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
WO2015124614A1 (en) | 2014-02-18 | 2015-08-27 | Mologen Ag | Covalently closed non-coding immunomodulatory dna construct |
US9549914B2 (en) | 2014-04-03 | 2017-01-24 | The Johns Hopkins University | Treatment of human cytomegalovirus by modulating Wnt |
US11957788B2 (en) | 2014-06-04 | 2024-04-16 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US10682365B2 (en) | 2014-12-31 | 2020-06-16 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
US11135279B2 (en) | 2015-01-15 | 2021-10-05 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2016113644A1 (en) | 2015-01-15 | 2016-07-21 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US10653764B2 (en) | 2015-01-15 | 2020-05-19 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2016183371A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for the treatment or prevention of ischemic tissue damage |
US10124050B2 (en) | 2015-07-21 | 2018-11-13 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
US11020469B2 (en) | 2015-07-21 | 2021-06-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
WO2017013548A1 (en) | 2015-07-21 | 2017-01-26 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
US11578331B2 (en) | 2015-09-09 | 2023-02-14 | Gilead Sciences, Inc. | Combination comprising immunostimulatory oligonucleotides |
US11583581B2 (en) | 2015-09-21 | 2023-02-21 | Gilead Sciences, Inc. | Methods of treating a retroviral infection |
US10786561B2 (en) | 2015-11-20 | 2020-09-29 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2017085586A1 (en) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
US11542335B2 (en) | 2016-08-25 | 2023-01-03 | Hoffmann-La Roche Inc. | Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R) |
US11498968B2 (en) | 2016-12-22 | 2022-11-15 | Hoffmann-La Roche Inc. | Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment |
US11413344B2 (en) | 2017-01-20 | 2022-08-16 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2018134693A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
US11806364B2 (en) | 2017-09-28 | 2023-11-07 | Industry-Academic Cooperation Foundation, Yonsei University | Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof |
WO2019066571A2 (en) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and uses thereof |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
US11434292B2 (en) | 2018-05-23 | 2022-09-06 | Pfizer Inc. | Antibodies specific for CD3 and uses thereof |
WO2020208502A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
CN114450014A (en) * | 2019-06-14 | 2022-05-06 | G科技生物有限责任公司 | Activated lymphocytic cells and methods of using the same for treating cancer and infectious disorders |
WO2021154745A1 (en) | 2020-01-27 | 2021-08-05 | Oregon State University | Gonorrhea subunit vaccine |
WO2022097010A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
WO2022249106A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2022249107A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7935675B1 (en) | Immunostimulatory nucleic acid molecules | |
US7713529B2 (en) | Methods for treating and preventing infectious disease | |
EP0948510B1 (en) | Immunostimulatory nucleic acid molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97199352.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09136138 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page |
Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 52424/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 335397 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2270345 Country of ref document: CA Ref document number: 2270345 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1998 520784 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997003873 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997947311 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997947311 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997003873 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997947311 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997003873 Country of ref document: KR |